Medical Cannabis for Dementia: A Complete Patient Resource Guide

Living with dementia can bring many changes, but you still deserve treatment that focuses on your comfort, dignity, and quality of life. If symptoms such as pain, poor sleep, agitation, anxiety, or loss of appetite continue despite other treatments, medical cannabis treatment may be worth discussing with your clinician. This guide explains what different types of dementia involve, how medical cannabis may fit into your care plan, and how to approach treatment safely with realistic expectations and clear symptom goals.

1. Understanding Dementia as a Group of Disorders

1.1 What Dementia Means

Dementia is not a single illness. It is a medical term that describes a group of symptoms affecting memory, thinking, language, judgment, and daily functioning. These changes become significant enough to interfere with everyday activities such as managing finances, preparing meals, taking medications, or having conversations. Dementia develops because brain cells become damaged or stop working as they should. It is important to know that dementia is not a normal part of getting older. While many people notice small memory changes with age, dementia causes ongoing cognitive decline that gradually affects independence. The symptoms often progress over time, although the rate of change varies from person to person. Understanding what dementia is helps you make informed treatment decisions. If symptoms such as chronic pain, poor appetite, anxiety, sleep disruption, or distress reduce your quality of life, medical cannabis may become one part of a broader care plan. The goal is not to reverse dementia, but to help manage specific symptoms that affect your comfort and daily well-being under careful medical supervision.

1.2 Why Dementia Is Not One Disease

Many people think dementia and Alzheimer's disease mean the same thing, but they do not. Dementia is an umbrella term that includes several different disorders. Each type affects the brain differently and may produce unique combinations of memory problems, movement changes, behavior, language difficulties, or visual symptoms. For example, Alzheimer's disease usually begins with memory loss, while vascular dementia often affects planning, decision-making, and thinking speed after reduced blood flow to the brain. Lewy body dementia may cause visual hallucinations and movement problems, while frontotemporal dementia often changes personality, behavior, or language before memory becomes severely affected. Knowing which type of dementia you have helps your healthcare team create a treatment plan that fits your needs. It also helps determine whether medical cannabis could be appropriate for symptoms such as pain, appetite loss, sleep disturbance, or agitation. Your diagnosis provides valuable information that guides product selection, dosing decisions, monitoring, and realistic treatment goals.

1.3 Mild, Moderate, and Advanced Dementia

Dementia progresses differently for every person, but healthcare professionals often describe it as mild, moderate, or advanced. These stages help explain how thinking abilities, communication, physical function, and daily independence change over time. They also help guide treatment planning and support needs. During mild dementia, you may still manage many daily activities independently while noticing increasing forgetfulness, difficulty learning new information, or occasional confusion. In moderate dementia, you may need help with medications, finances, meals, or personal care. Advanced dementia often requires full-time assistance because communication, mobility, swallowing, and self-care become much more difficult. Medical cannabis goals may also change as dementia progresses. Early treatment may focus on relieving chronic pain while helping you stay active and comfortable. Later treatment may place greater emphasis on easing distress, supporting appetite, improving sleep, or making personal care less uncomfortable. Regular follow-up allows your clinician to adjust your treatment plan as your needs change.

2. Identifying the Specific Dementia Disorder

2.1 Alzheimer's Disease

Alzheimer's disease is the most common cause of dementia. It usually begins with difficulty remembering recent conversations or learning new information. As the condition progresses, you may experience increasing confusion, become disoriented in familiar places, struggle to find words, or have difficulty making everyday decisions. Over time, Alzheimer's disease may also affect mood, sleep, appetite, and behavior. Some people become anxious or restless, while others lose interest in activities they once enjoyed. These symptoms can reduce the quality of life for both patients and families. When symptoms such as ongoing pain, appetite loss, sleep disruption, or distress remain difficult to manage, a carefully supervised medical cannabis trial may be considered. Treatment should always focus on measurable symptom relief while balancing comfort with clear thinking and daily function.

2.2 Vascular and Mixed Dementia

Vascular dementia develops when reduced blood flow damages areas of your brain. This may happen after one major stroke, several smaller strokes, or long-term disease affecting the blood vessels. You may notice slower thinking, difficulty planning, poor concentration, reduced judgment, or changes in walking and balance. Some people experience a stepwise decline, with noticeable changes after each vascular event followed by periods of relative stability. Others develop more gradual symptoms. Mixed dementia occurs when vascular damage appears alongside another condition, most often Alzheimer’s disease. This combination can produce memory loss together with problems involving organization, movement, attention, or emotional control. Before considering medical cannabis, your clinician may review:

• Your history of strokes, heart disease, and blood pressure changes
• Medicines such as blood thinners, heart drugs, and blood pressure treatments
• Your balance, walking ability, dizziness, and previous falls
• The symptom you want to treat, such as pain, poor sleep, appetite loss, or distress
• The amount of supervision available during dosing

This review helps your clinician choose a product and dose that fit your health needs. A carefully monitored cannabis trial may support comfort or symptom control, but the plan should account for cardiovascular health, mobility, and medication interactions. Starting with a low dose and tracking your response allows your healthcare team to protect your function while assessing whether the treatment provides meaningful benefit.

2.3 Lewy Body, Frontotemporal, and Other Dementias

Several less common disorders also fall under the dementia umbrella. Lewy body dementia often causes fluctuating attention, visual hallucinations, movement problems, and sleep disturbances. Frontotemporal dementia primarily affects personality, behavior, decision-making, or language. Other forms may develop after Parkinson's disease, traumatic brain injury, long-term alcohol misuse, or certain rare neurological conditions. Each disorder presents different challenges, which is why an accurate diagnosis is essential before considering medical cannabis. Some people are especially sensitive to THC, while others may benefit from carefully selected products aimed at improving pain, sleep, appetite, or distress without creating unnecessary side effects. Rather than assuming one treatment works for every form of dementia, your clinician can tailor recommendations to your diagnosis, symptoms, current medications, and overall health. This individualized approach gives you the best opportunity to achieve meaningful symptom relief while maintaining as much independence, comfort, and participation in daily life as possible.

3. Confirming the Diagnosis Before Considering Cannabis

3.1 Why Memory Problems Require Medical Evaluation

Memory problems do not always mean dementia. Several treatable medical conditions can cause forgetfulness, confusion, poor concentration, or changes in behavior. These may include depression, thyroid disease, vitamin deficiencies, sleep disorders, medication side effects, hearing loss, dehydration, infection, or delirium. A medical evaluation helps your clinician identify whether your symptoms come from dementia, another health problem, or several conditions occurring together. This step is important before starting medical cannabis because treatment works best when your healthcare team understands what is causing your symptoms. For example, cannabis may help manage persistent pain or nausea, but it would not treat a urinary infection, low vitamin level, or medication reaction. Addressing those causes first may considerably improve your thinking and comfort. A clear diagnosis also gives you a useful baseline. Your clinician can compare your memory, alertness, mood, sleep, and daily function before and after treatment. This makes it easier to determine whether cannabis provides meaningful relief without creating unwanted cognitive changes.

3.2 Tests Used to Evaluate Cognitive Decline

Your dementia evaluation may include several tests, each serving a specific purpose. The goal is to understand how your thinking has changed, how those changes affect daily life, and whether another condition may be contributing. Your healthcare team may review:

• Your medical history, symptoms, and family observations
• Prescription medicines, nonprescription products, and supplements
• Memory, attention, language, and problem-solving skills
• Balance, reflexes, strength, movement, and coordination
• Blood tests for thyroid problems, vitamin deficiencies, infection, or metabolic changes
• Brain imaging to look for strokes, tumors, injury, or other structural changes
• Your ability to cook, drive, manage money, take medicine, and complete personal care

These findings help your clinician identify the likely type and stage of dementia. They also help determine whether you can manage cannabis independently or whether another person should assist with measuring, recording, and storing each dose. A thorough assessment supports a treatment plan that matches your abilities rather than relying on assumptions.

3.3 Why the Dementia Type Matters for Cannabis Decisions

The type of dementia you have can affect how you respond to cannabis. Lewy body dementia may involve visual hallucinations and strong sensitivity to psychoactive medicines. Vascular dementia may occur alongside blood pressure problems, stroke history, or difficulty walking. Frontotemporal dementia may affect impulse control and make unsupervised redosing more likely. Your physical symptoms matter as well. Swallowing problems may rule out certain oils, capsules, or edibles. Frequent dizziness or falls may require extra caution with THC. Hallucinations, heart disease, medication sensitivity, or movement disorders may lead your clinician to select a CBD-dominant product or a very low THC dose. This does not automatically prevent you from considering medical cannabis. It means your treatment should reflect your diagnosis, symptom priorities, and current abilities. A tailored plan gives you a better chance of receiving relief while preserving alertness, mobility, and participation in daily life.

4. Distinguishing Dementia From Delirium

4.1 How Delirium Differs From Progressive Dementia

Dementia usually develops gradually over months or years. Delirium appears much more suddenly, often within hours or days. You may become unusually confused, sleepy, restless, fearful, or unable to follow a conversation. Your alertness may also change throughout the day, with periods of clear thinking followed by severe confusion. Delirium is not simply a faster stage of dementia. It is often a sign that your body is dealing with an acute medical problem. People who already have dementia can also develop delirium, and the sudden change may be mistaken for normal disease progression. Recognizing the difference matters because delirium often improves when its cause is treated. If your thinking or behavior changes rapidly, medical cannabis should not be the first response. Your healthcare team should first look for infection, medication problems, dehydration, pain, or another urgent cause.

4.2 Common Causes of Sudden Cognitive Worsening

Many health problems can trigger delirium, especially in older adults or people with dementia. Common causes include urinary infections, respiratory infections, constipation, dehydration, uncontrolled pain, poor sleep, medication toxicity, withdrawal, and recent hospitalization. Even a small change can have a large effect. A new sleep medicine, missed prescription dose, reduced fluid intake, fever, or several nights of poor rest may cause sudden confusion or unusual behavior. Because the symptoms can resemble cannabis intoxication, timing and careful observation are important. Tell your clinician when the change began, whether it fluctuates, and what medicines or cannabis products were taken beforehand. This information helps separate delirium from a side effect, a dementia symptom, or a new medical problem. Once the cause is addressed, your treatment team can decide whether your cannabis plan should continue, pause, or change.

4.3 Why Cannabis Should Not Be Used to Mask Delirium

Cannabis should not be used to quiet sudden agitation, hallucinations, or confusion before the cause is understood. A sedating dose may make the person appear calmer while the underlying illness continues. It may also make it harder to judge alertness, hydration, breathing, balance, or neurological changes. This does not mean medical cannabis has no role in dementia care. It means timing matters. Cannabis may still help a stable, previously identified symptom such as chronic pain, nausea, appetite loss, or persistent sleep disruption. Sudden changes require medical assessment first. Seek prompt clinical guidance when confusion develops rapidly or is accompanied by fever, reduced alertness, repeated vomiting, weakness, changes in breathing, or a recent medication adjustment. After the urgent issue is treated, your clinician can review the cannabis plan and restart it cautiously when appropriate. This protects your safety while preserving medical cannabis as a useful option for ongoing symptom relief.

5. Understanding the Symptoms Cannabis Might Target

5.1 Symptoms Potentially Considered for Treatment

Medical cannabis may be considered when a specific symptom continues to reduce your comfort despite appropriate evaluation and treatment. In dementia care, the most relevant targets may include persistent pain, poor appetite, nausea, sleep disruption, anxiety, agitation, or distress. The goal is to address a defined problem rather than treat dementia as a whole. Your clinician will usually review possible causes before recommending cannabis. Pain may come from arthritis, neuropathy, an old fracture, or immobility. Poor sleep may result from pain, nighttime urination, anxiety, or an irregular sleep schedule. Identifying the cause helps your clinician decide whether cannabis is likely to fit your needs. A carefully supervised trial can then focus on measurable changes. You may notice fewer pain behaviors, better meal intake, longer periods of restful sleep, or less distress during care. These practical outcomes help show whether treatment is providing real value. According to a 2022 long-term observational study by Pautex et al., supervised THC and CBD treatment was associated with sustained improvements in agitation, rigidity, disabling behaviors, and daily care among patients with severe dementia, although larger controlled trials are still needed.

5.2 Symptoms Cannabis Is Unlikely to Correct

Medical cannabis may help manage certain symptoms, but it should not be expected to restore lost memories, reverse brain damage, permanently recover language, or stop dementia from progressing. Understanding this difference supports realistic treatment goals and prevents you from judging a useful treatment by an outcome it was never designed to produce. Cannabis works best when the target is specific and achievable. For example, it may help you feel more comfortable during movement, eat more consistently, settle more easily at night, or experience less nausea. These changes can still improve your daily quality of life, even when the underlying dementia remains. Your clinician should explain what improvement would look like before treatment begins. This gives you and the people supporting you a clear way to evaluate the benefit. It also helps prevent unnecessary dose increases when the original goal has already been reached.

5.3 Choosing One Primary Symptom Target

Choosing one main symptom gives your cannabis trial a clear purpose. When you try to address pain, sleep, appetite, agitation, and anxiety at the same time, it becomes difficult to tell whether the product helped or whether another change affected the result. A single target creates a more reliable starting point. Your primary symptom should be specific, observable, and important to your daily comfort. Useful targets may include:

• Pain during bathing, dressing, or walking
• Waking several times during the night
• Eating less than half of each meal
• Becoming distressed during evening care
• Experiencing repeated nausea that limits food or fluid intake

Before the first dose, record how often the symptom occurs, how long it lasts, and how strongly it affects your function. You might track the number of nighttime awakenings, the amount of food eaten, the length of an agitation episode, or your willingness to move despite pain. This baseline gives your clinician something concrete to compare with later observations. Once the primary symptom improves, your treatment team can decide whether to maintain the same plan or consider another goal. This focused method reduces unnecessary dose changes and helps identify the smallest amount that produces useful relief. It also makes conversations with your clinician clearer because you can describe exactly what changed rather than relying on a general impression.

6. Medical Cannabis and the Brain

6.1 The Endocannabinoid System in Simple Terms

Your body has an endocannabinoid system that helps regulate pain, appetite, mood, sleep, stress responses, and nervous system activity. This system includes naturally occurring compounds, receptors, and enzymes that work together to maintain balance across several bodily processes. In a 2021 peer-reviewed review by Lu and Mackie, the endocannabinoid system is described as a widespread signaling network that regulates cognition, pain, appetite, stress responses, and other physiological processes rather than controlling only one bodily function.  Cannabinoids from cannabis can interact with this system. THC binds strongly to receptors involved in memory, perception, appetite, movement, and emotional response. CBD works differently and may influence several signaling pathways without usually producing the same intoxicating effects as THC. This interaction helps explain why medical cannabis may affect more than one symptom at a time. A product chosen for pain may also influence sleep or appetite. Because these effects can overlap, careful dosing and symptom tracking are essential.

6.2 How THC Can Affect Cognition and Perception

THC may reduce pain, support appetite, ease nausea, or help some people settle at night. It can also affect attention, short-term memory, reaction time, coordination, and perception. These effects depend on the dose, the product, your previous cannabis exposure, and your sensitivity. When you already live with dementia, even a small change in alertness or balance may be noticeable. A dose that is too high may cause confusion, anxiety, dizziness, unusual sleepiness, or difficulty following familiar routines. These effects do not mean THC cannot be considered. They show why treatment should begin with a very small amount. Your clinician can adjust the dose gradually while monitoring comfort, communication, walking, appetite, and behavior. The aim is to gain symptom relief without causing unnecessary intoxication or loss of function.

6.3 How CBD Differs From THC

CBD does not usually produce the same intoxicating effect as THC. For this reason, a CBD-dominant product may be considered when you are sensitive to cognitive changes, hallucinations, anxiety, or daytime sedation. It may also be easier to assess during daytime use when maintaining alertness is important. CBD is not completely free of side effects. It may cause fatigue, digestive discomfort, changes in appetite, or mood changes. It can also interact with medications by affecting how the liver processes certain drugs. Your clinician or pharmacist should review your full medication list before treatment begins. This is especially important if you take blood thinners, seizure medicines, sedatives, antidepressants, or heart medications. A careful review allows CBD to be considered with appropriate monitoring rather than treated as automatically risk-free.

7. What Research Shows About Cannabis and Dementia

7.1 Evidence for Treating Dementia Related Symptoms

Research on medical cannabis for dementia remains limited, but some studies suggest that cannabinoids may help selected symptoms such as agitation, poor appetite, sleep disruption, pain, or distress. The strongest potential role is symptom management rather than treatment of the underlying dementia disorder. A 2021 peer-reviewed narrative review by Outen et al. found that early clinical evidence suggests cannabinoids may reduce agitation in Alzheimer’s disease by influencing neurotransmitter activity, sleep rhythms, anxiety, inflammation, and related symptoms, although larger controlled trials remain necessary.  Results differ because studies have used different products, doses, and patient groups. Some research has examined synthetic cannabinoids, while other studies have tested plant-derived products containing THC, CBD, or both. This makes direct comparison difficult. A supervised trial may still be reasonable when a specific symptom remains difficult to control. Your clinician can use the available evidence together with your diagnosis, medication list, health history, and treatment goals. Careful monitoring is important because a helpful response in one patient does not guarantee the same result in another.

7.2 Why Symptom Improvement Is Not Disease Modification

Symptom improvement means that a treatment helps you feel or function better without changing the disease process itself. For example, cannabis may help you eat more comfortably, sleep for longer periods, experience less pain, or show fewer signs of distress. These benefits can still matter greatly. Better comfort may help you participate in meals, personal care, conversation, movement, or familiar activities. However, these changes should not be confused with restored memory or slowed brain degeneration. Medical cannabis has not been proven to stop, reverse, or cure dementia. Your established dementia care should continue, including prescribed medications, specialist follow-up, physical activity, nutrition support, and management of other health conditions. Cannabis works best when considered as one part of a broader plan focused on comfort and quality of life.

7.3 Limitations of the Available Evidence

Current dementia and cannabis research has several important limitations:

• Many studies include only a small number of patients
• Treatment periods are often short
• Products and cannabinoid ratios vary widely
• Dementia types are sometimes grouped together
• Long-term safety data remain limited
• Results may rely heavily on caregiver observation
• Synthetic cannabinoids may not reflect plant-derived products

These limits do not mean cannabis cannot help you. They mean that your treatment should be individualized and carefully reviewed. A clear symptom target, a low starting dose, a stable product, and a written journal can provide useful information about your own response. Your experience becomes easier to interpret when your healthcare team measures practical outcomes such as meal intake, sleep duration, movement, pain behaviors, or the frequency of agitation. This approach allows you to pursue potential benefits while avoiding assumptions unsupported by evidence.

8. Setting Realistic Treatment Goals

8.1 Comfort Goals

Comfort goals focus on reducing symptoms that make daily life difficult or unpleasant. These may include pain, nausea, poor appetite, nighttime distress, muscle tension, or discomfort during bathing and dressing. Medical cannabis may be considered when these symptoms remain troublesome despite other reasonable approaches. A useful goal should describe what improved comfort would look like. You may want to move with fewer pain behaviors, sit through a meal without nausea, settle more easily at bedtime, or accept personal care with less distress. Clear goals help your clinician judge whether the product is helping. They also prevent dose increases based only on sleepiness or reduced activity. The aim is not simply to make you quieter. It is to help you feel more comfortable while preserving as much alertness and engagement as possible.

8.2 Functional and Participation Goals

Functional goals focus on what you can do rather than only how a symptom feels. You may want to eat more of each meal, walk to the bathroom with less discomfort, join a familiar activity, remain seated during a conversation, or tolerate dressing more easily. These goals are especially useful when it is difficult for you to describe symptoms directly. Family members and clinicians can observe whether your participation improves after treatment. They can also compare your response with your usual level of function. Medical cannabis should support meaningful activity whenever possible. A dose that reduces pain but leaves you too sleepy to eat or communicate may need adjustment. Your healthcare team can refine the product, amount, or timing until the balance between comfort and participation becomes more suitable.

8.3 Safety and Quality of Life Goals

Safety goals help protect your independence and prevent treatment from creating new problems. These may include avoiding falls, excessive sedation, frightening hallucinations, conflict during care, emergency visits, or reduced food and fluid intake. Quality of life includes more than symptom reduction. It may involve enjoying meals, recognizing familiar people, resting comfortably, listening to music, spending time outdoors, or making simple choices. Your treatment plan should reflect the activities and experiences that matter most to you. Before starting cannabis, your clinician should define both the hoped-for benefit and the limits of acceptable side effects. Regular review then shows whether the treatment continues to support your comfort, function, and personal priorities. If the balance changes, the dose or product can be adjusted without abandoning medical cannabis as a treatment option.

9. Deciding Whether a Cannabis Trial Is Appropriate

9.1 When a Carefully Supervised Trial May Be Considered

A carefully supervised cannabis trial may be considered when a persistent symptom continues to cause distress despite appropriate evaluation and treatment. This may include pain, poor appetite, nausea, sleep disruption, anxiety, or severe agitation that has not improved enough with environmental changes, routine adjustments, or established therapies. Your clinician should first confirm that the symptom has been clearly identified and that treatable causes have been addressed. For example, agitation may come from pain, infection, constipation, hunger, fear, or overstimulation. Once those possibilities have been reviewed, cannabis may become a reasonable option for symptom relief. The best trials begin with one measurable goal and a low starting dose. Your healthcare team can then monitor whether you become more comfortable, eat more consistently, sleep better, move with less pain, or experience fewer episodes of distress. This structured approach supports useful treatment decisions.

9.2 When Cannabis May Present Greater Risk

Some health conditions require a more cautious approach, but they do not always rule out medical cannabis. Your clinician may need to adjust the product, dose, timing, or level of supervision when you have:

• Frequent falls or severe balance problems
• Unstable heart disease or significant blood pressure changes
• Active psychosis or uncontrolled hallucinations
• Severe swallowing difficulty
• Extreme sensitivity to psychoactive medicines
• Limited supervision during dosing
• Repeated confusion about whether a dose was already taken

These factors matter because THC can affect coordination, alertness, perception, and judgment. A CBD-dominant product, a smaller dose, a slower adjustment schedule, or a different route of administration may offer a more suitable approach. The decision should focus on your individual situation rather than a single diagnosis or risk factor. With clinician oversight, many concerns can be managed through careful product selection, written instructions, close observation, and regular follow-up.

9.3 Questions to Resolve Before the First Dose

Before the first dose, your treatment team should create a clear plan. Everyone involved should know what symptom is being treated, what product will be used, how much will be given, and who will administer it. The plan should also state how long to wait before considering another dose, what changes to record, and what side effects require a pause. Storage should be secure, and the product should remain in its original labeled packaging. According to a 2021 expert consensus study by Bhaskar et al., medical cannabis treatment should begin with individualized goals, gradual dose adjustment, and follow-up every two to four weeks during initiation so clinicians can assess benefits, adverse effects, and dosing needs.  A follow-up date is equally important. Your clinician needs enough information to decide whether the treatment is helping, whether the dose should remain the same, or whether another product may be more appropriate. Clear preparation gives the trial a better chance of producing useful and reliable results.

10. Patient Consent and Decision-Making Capacity

10.1 Supporting the Patient’s Own Choices

A dementia diagnosis does not automatically remove your right to participate in medical decisions. You should still be spoken to directly, given understandable information, and allowed enough time to ask questions and express your preferences. Your clinician can support your involvement by using simple language, discussing one idea at a time, and checking whether you understand the purpose of treatment. Visual aids, written instructions, and familiar support people may also help. Even when you need assistance, your values still matter. You may have clear preferences about comfort, alertness, pain relief, appetite, or how much sedation feels acceptable. These preferences should guide the cannabis plan as much as possible.

10.2 Assessing Capacity for a Cannabis Decision

Decision-making capacity refers to your ability to understand a specific treatment choice at a specific time. It is not an all-or-nothing judgment. You may be able to make some medical decisions independently, but you need support with more complex choices. For a cannabis decision, your clinician may assess whether you can understand why the treatment is being considered, describe likely benefits and side effects, compare it with other options, and communicate a consistent choice. Your ability to follow basic instructions and avoid repeated dosing may also be reviewed. Capacity can change over time and may fluctuate during the day. A conversation held when you are rested, comfortable, and alert may produce a more accurate assessment than one held during pain, illness, or confusion.

10.3 When a Healthcare Proxy or Legal Representative Is Involved

A healthcare proxy or legal representative may become involved when you can no longer make a particular treatment decision independently. This person should use your known values, past statements, and treatment preferences whenever possible. The representative should not simply choose what is easiest for others. The goal is to make the decision you would likely make for yourself or, when your wishes are unknown, select the option that best supports your comfort, dignity, and safety. You should still remain involved as much as possible. Your verbal responses, facial expressions, behavior, and willingness to take the product all provide important information. Even when another person holds legal authority, your experience and preferences should continue to shape the treatment plan.

11. Preserving Patient Autonomy During Treatment

11.1 Avoiding Automatic Loss of Control After Diagnosis

A dementia diagnosis does not mean you immediately lose control over medical decisions. Your ability to understand information, express preferences, and participate in treatment may remain strong in many areas, especially during earlier stages. Capacity should be assessed for the specific decision being made rather than assumed from the diagnosis alone. You should receive information in clear language and have enough time to consider it. Your clinician may discuss the treatment during the time of day when you are most alert and comfortable. A familiar person may join the conversation, but that person should support your voice rather than speak over you. Medical cannabis decisions should reflect your goals. You may value pain relief, appetite, sleep, alertness, or the ability to join daily activities. These priorities should remain central throughout treatment, even when you need increasing assistance.

11.2 Recognizing Verbal and Nonverbal Refusal

You may express refusal with words, but dementia can make verbal communication difficult. Your actions and emotional responses can also show that you do not want a dose. The people assisting with treatment should watch for consistent signs of discomfort or unwillingness. Possible signs of refusal include:

• Saying no or asking the person to stop
• Turning your head or body away
• Closing your mouth
• Pushing the product or administrator away
• Becoming visibly distressed
• Repeatedly resisting administration

A single movement may not always indicate refusal, especially if you are confused or uncomfortable. However, repeated resistance should be taken seriously. The administrator should pause, speak calmly, check for pain or fear, and try again later only when appropriate.

11.3 Avoiding Covert Administration

Cannabis should not be hidden in your food or drink simply because taking it openly is difficult. Covert administration can interfere with trust, consent, accurate dosing, and your ability to report how the product affects you. In rare situations, a legal representative and the clinical team may consider concealing medication as part of a formal care process. This should involve documented medical reasoning, legal authority, pharmacy guidance, and clear review procedures. It should never become an informal shortcut. Whenever possible, your care team should select a product you can accept knowingly and comfortably. A simple routine, a familiar administrator, a suitable flavor, or an easier route may solve the problem while preserving your dignity and participation.

12. Establishing a Cognitive and Functional Baseline

12.1 Recording Memory and Attention Before Treatment

A baseline describes how you usually think, communicate, and function before medical cannabis begins. This information helps your clinician distinguish your existing dementia symptoms from treatment effects. Record your usual orientation, recent memory, attention, alertness, conversation ability, and capacity to follow simple instructions. Note whether confusion appears at certain times of day and whether fatigue, pain, hunger, or noise makes it worse. The baseline does not need to be a formal medical test. Clear observations from several ordinary days can provide useful information. Once treatment starts, your healthcare team can compare later changes with this record and determine whether you appear more comfortable, more confused, more alert, or unchanged.

12.2 Recording Mobility and Daily Function

Your ability to move and complete daily activities should also be documented before the first dose. This is especially important because THC may affect balance, coordination, blood pressure, and reaction time. A 2021 peer-reviewed pilot study by Workman et al. of older chronic cannabis users showed slower walking speeds and a greater likelihood of falling than nonusers, supporting the need to document gait and balance before treatment begins.  Record how much assistance you normally need with walking, standing, transfers, toileting, dressing, eating, bathing, and medication use. Note whether you use a cane, walker, wheelchair, grab bar, or another support. Your treatment team should also record recent falls, dizziness, freezing, weakness, or difficulty rising from a chair. These details help clinicians choose an appropriate dose and timing. They also make it easier to recognize whether treatment supports easier movement or causes unwanted physical slowing.

12.3 Recording Mood and Behavior

Mood and behavior can change from one day to the next, so a baseline should reflect your usual patterns rather than a single isolated episode. Track anxiety, pacing, irritability, resistance to care, hallucinations, appetite, sleep, and social engagement. Record when behaviors occur, what seems to trigger them, and what usually helps. For example, agitation may appear during bathing, in noisy rooms, or late in the day. Reassurance, food, movement, music, or quiet time may reduce it. This information helps your clinician judge cannabis fairly. Improvement should mean that you appear more comfortable and engaged, not simply quieter because you are sleepy. A detailed baseline supports safer dosing and more accurate treatment decisions.

13. Identifying the Cause of Behavioral Changes

13.1 Pain, Illness, and Physical Discomfort

Behavioral changes are often a form of communication. When dementia makes it difficult to explain discomfort, your actions may reveal that something is wrong. Pacing, shouting, resisting care, restlessness, or sudden withdrawal can all signal physical distress rather than a change in personality. Many medical conditions can contribute to these behaviors. Arthritis, constipation, urinary retention, dental pain, pressure injuries, hunger, thirst, poorly fitting clothing, or medication side effects may all increase discomfort. Even a minor illness can make confusion and distress more noticeable. Before adjusting your cannabis dose, your healthcare team should look for these treatable causes. If ongoing pain remains the main problem after evaluation, a carefully supervised medical cannabis trial may help improve comfort. Treating the true source of distress gives you the best opportunity to feel better while avoiding unnecessary medication changes.

13.2 Environmental and Communication Triggers

Your surroundings can have a powerful effect on how you feel throughout the day. Loud television, crowded rooms, rushed caregivers, unfamiliar people, poor lighting, or sudden changes in routine may increase confusion and anxiety. When too much is happening at once, even simple tasks can become overwhelming. Communication style also matters. Long explanations, rapid instructions, or repeated corrections may increase frustration when your brain needs more time to process information. Speaking calmly, giving one direction at a time, and allowing time to respond often produces a better experience. Medical cannabis should work alongside these supportive approaches rather than replace them. A quieter environment, familiar routines, and respectful communication may reduce distress on their own. When cannabis is added to an already supportive care plan, it becomes easier to judge whether it provides additional symptom relief.

13.3 Emotional and Social Needs

Not every behavioral change comes from physical illness. Dementia can make familiar places seem unfamiliar and ordinary situations feel frightening. You may become distressed because you feel lonely, bored, frightened, overwhelmed, or unable to understand what is happening around you. Loss of independence can also affect emotional well-being. Needing help with dressing, bathing, eating, or walking can be frustrating, even when the assistance is kind and necessary. Feeling ignored or corrected repeatedly may further increase distress. Your treatment plan should consider these emotional needs alongside medical symptoms. Meaningful conversation, favorite music, gentle movement, familiar photographs, enjoyable activities, and supportive relationships all contribute to comfort. When emotional needs are addressed together with carefully supervised medical cannabis, many patients experience a calmer, more reassuring daily routine.

14. Medical Cannabis for Pain in Dementia

14.1 Recognizing Pain When the Patient Cannot Describe It

Pain is common in dementia, yet many people find it difficult to explain exactly where it hurts or how severe it feels. Instead of describing pain with words, you may show it through changes in movement, facial expression, sleep, appetite, or behavior. These changes deserve careful attention because untreated pain can reduce comfort and quality of life. According to a 2021 systematic review by Felton et al., validated dementia pain tools assess observable signs such as facial expressions, vocalizations, body movements, and changes during care, as self-reporting often becomes less reliable as cognitive impairment advances.  Common signs that pain may be present include:

• Grimacing or frowning
• Guarding part of the body
• Moaning or crying out
• Restlessness or pacing
• Pulling away during movement
• Sleeping poorly
• Eating less than usual
• Becoming resistant during bathing or dressing

Recognizing these patterns helps your healthcare team identify pain earlier. When pain is confirmed and continues despite appropriate treatment, medical cannabis may become part of a broader plan aimed at improving comfort and daily function.

14.2 Conditions That May Cause Persistent Pain

Many health conditions can cause ongoing pain in people living with dementia. Arthritis is one of the most common causes, but nerve damage, spinal disorders, previous fractures, pressure injuries, headaches, muscle stiffness, cancer, and long periods of limited movement may also contribute. Pain may become more noticeable during transfers, walking, dressing, or personal care. Some people appear comfortable while resting but show obvious discomfort once movement begins. This is why observing daily activities often provides more useful information than asking about pain only while sitting quietly. Your clinician should identify the likely source of pain before recommending treatment. Medical cannabis may help relieve persistent pain in selected patients, particularly when discomfort continues despite other appropriate therapies. A clear diagnosis makes it easier to choose realistic treatment goals and monitor your progress.

14.3 Measuring Whether Cannabis Is Helping Pain

Pain relief should be measured through meaningful changes in daily life rather than relying only on general impressions. Before treatment begins, record how pain affects your movement, sleep, eating, mood, and participation in personal care. These observations provide a valuable comparison during follow-up. After starting medical cannabis, look for practical improvements such as easier walking, fewer pain-related facial expressions, greater willingness to participate in bathing or dressing, improved sleep, or less need for additional pain medication. Family members and caregivers may notice changes that you are unable to describe yourself. Regular reviews with your clinician help keep the treatment plan focused on meaningful results. If the chosen product improves comfort without causing excessive sleepiness or reducing your daily participation, your current dose may remain appropriate. If the balance changes, adjustments can be made while keeping your primary goal of lasting pain relief and improved quality of life in focus.

15. Medical Cannabis for Agitation and Aggression

15.1 Understanding Agitation as Communication

Agitation may include pacing, shouting, repeated questions, resisting care, throwing objects, or striking out. These behaviors can feel alarming, but they often communicate pain, fear, confusion, frustration, or an unmet physical need. Dementia may limit your ability to explain what feels wrong, so behavior becomes an important source of information. Your healthcare team should look at what happened before the behavior began. You may become distressed during bathing because the water feels cold, resist dressing because movement causes pain, or pace because you need the toilet. Agitation that appears later in the day may also relate to fatigue, poor lighting, hunger, or changes in routine. Understanding the reason behind the behavior supports more effective treatment. Medical cannabis may be considered when severe agitation continues after likely triggers have been identified and addressed. The aim is to reduce distress while helping you remain alert, comfortable, and involved in daily life.

15.2 Trying Non-Drug Strategies First

Supportive approaches can often reduce agitation and may also help medical cannabis work more predictably. These strategies do not dismiss your symptoms. They address common causes of distress and create a calmer setting in which your response to treatment can be measured accurately. Helpful approaches may include:

• Speaking slowly and giving one instruction at a time
• Keeping meals, sleep, bathing, and medication routines familiar
• Reducing noise, crowding, and unnecessary activity
• Offering food, fluids, toileting, or pain relief
• Playing familiar music or providing a meaningful activity
• Allowing safe walking or gentle movement
• Moving to a quiet, well-lit room
• Avoiding arguments, corrections, or rushed care

These measures may solve the immediate problem or reduce the amount of medication you need. When agitation remains severe, your clinician can consider medical cannabis as part of the plan rather than relying on it alone.

15.3 Evaluating a Cannabis Trial for Severe Agitation

A cannabis trial should begin with a clearly defined behavior. Instead of recording that you were difficult or upset, your care team might document that you paced for forty minutes, shouted during bathing, or attempted to leave the home three times during the evening. The record should include how often the behavior occurs, how long it lasts, what triggers it, and whether reassurance or redirection helps. After each cannabis dose, your team should note changes in distress, communication, movement, alertness, and participation. A useful response means you appear more comfortable, not simply too sleepy to express your needs. Your clinician should also establish limits before treatment begins. Cannabis may need adjustment if agitation increases or if you develop confusion, hallucinations, poor balance, or excessive drowsiness. When the product reduces distress without limiting your function, the lowest effective dose can be continued and reviewed regularly.

16. Medical Cannabis for Anxiety and Distress

16.1 Recognizing Anxiety in Dementia

Anxiety may not always appear as a clear statement that you feel worried. You may repeatedly ask where you are, request reassurance, cling to a familiar person, refuse to enter a new setting, or become restless when routines change. Trembling, rapid breathing, irritability, pacing, and fear of being alone can also suggest anxiety. Dementia may make it harder to understand unfamiliar places, people, or instructions. A situation that seems ordinary to someone else may feel unsafe when you cannot remember why it is happening. Pain, hunger, poor hearing, fatigue, and overstimulation may increase this distress. Identifying the pattern helps your healthcare team select the right response. If anxiety remains persistent despite reassurance and environmental support, medical cannabis may be considered. Treatment should focus on helping you feel safer and calmer while preserving communication, mobility, and awareness.

16.2 Understanding Why THC May Worsen Anxiety

A small amount of THC may help some patients feel calmer, sleep more comfortably, or experience less pain-related distress. However, a dose that is too high may produce the opposite response. You may feel panicked, suspicious, confused, or unusually aware of sounds, lights, and movement around you.  According to a 2022 peer-reviewed review by Lichenstein et al., controlled human studies consistently found that THC can increase anxiety, with stronger effects often appearing at higher doses and among people with less regular cannabis exposure. For this reason, getting proper dosing from a marijuana doctor is necessary. These effects can be especially difficult when dementia already makes the environment feel unfamiliar. Racing thoughts, altered perception, or difficulty recognizing people may increase fear rather than relieve it. The risk depends on the dose, your sensitivity, previous cannabis exposure, and the type of dementia you have. This is why clinicians usually begin with very low THC exposure and adjust slowly. A cautious approach does not prevent you from receiving possible benefits. It helps your treatment team find an amount that supports comfort without creating avoidable anxiety or perceptual changes.

16.3 Using a Low Intoxication Strategy

A low intoxication strategy aims to relieve anxiety while protecting your alertness and ability to function. Your clinician may consider a CBD-dominant product or a formulation containing only a very small amount of THC. Product selection should reflect your medication list, hallucination history, balance, and sensitivity to psychoactive effects. Cannabis should be introduced in a calm, familiar place where you can be observed closely. Your care team should avoid making several treatment changes at once. Keeping the product, dose, route, and timing stable makes your response easier to interpret. After each adjustment, monitor your breathing, facial expression, conversation, movement, sleepiness, and willingness to engage with others. Improvement should look like reduced fear, less repetitive reassurance seeking, and greater comfort during familiar activities. If anxiety increases, the dose can be reduced or the product reconsidered without ruling out other carefully selected cannabis options.

17. Medical Cannabis for Sleep Disturbance and Sundowning

17.1 Identifying the Actual Sleep Problem

Sleep problems in dementia can have several causes, so your healthcare team should identify the pattern before choosing a treatment. You may struggle to fall asleep, wake repeatedly, sleep for long periods during the day, or become active during the night. Pain, nighttime urination, restless legs, medication effects, sleep apnea, and environmental noise may also interrupt rest. A sleep record can show when you go to bed, how long you remain awake, how often you rise, and how alert you feel the next morning. This information helps your clinician decide whether medical cannabis may address pain, anxiety, or another symptom that interferes with sleep. The treatment goal should be restful sleep, not simply heavy sedation. A suitable cannabis plan should help you sleep more comfortably while allowing you to wake, communicate, eat, and move the following day safely.

17.2 Understanding Sundowning

Sundowning refers to increased confusion, restlessness, wandering, fear, or agitation in the late afternoon or evening. You may ask to go home, search for someone, resist care, pace repeatedly, or become distressed as daylight fades. Possible triggers include:

• Physical or mental fatigue
• Hunger, thirst, pain, or toileting needs
• Shadows caused by poor lighting
• Excessive daytime sleeping
• Noise or activity during evening routines
• Changes in caregivers or surroundings
• Medication effects that appear later in the day

Improving lighting, maintaining a familiar routine, offering food and fluids, and reducing evening stimulation may lessen these symptoms. If significant distress continues, your clinician may consider medical cannabis as part of a structured plan. Timing matters because the product should begin working when symptoms usually appear without causing unnecessary daytime sleepiness.

17.3 Measuring More Than Sedation

A cannabis dose should not be judged successful only because you sleep longer or become quieter. Your care team should examine whether your sleep is more restorative and whether you function better the following day. Track total sleep time, nighttime awakenings, wandering, bathroom trips, morning alertness, daytime naps, appetite, balance, and participation in familiar activities. A useful response may include fewer distressed awakenings, less nighttime pacing, and improved morning comfort. Excessive sleepiness, difficulty standing, reduced eating, or loss of interest in daily activities may indicate that the dose is too strong. Your clinician can reduce the amount, change the timing, or consider a product with less THC. Careful adjustments can help you find a plan that supports both nighttime rest and daytime quality of life.

18. Medical Cannabis for Appetite and Weight Loss

18.1 Identifying Why the Patient Is Eating Less

Reduced eating can occur for many reasons in dementia. You may have dental pain, constipation, nausea, depression, swallowing difficulty, altered taste, or medication side effects. You may also struggle to recognize food, use utensils, stay focused during meals, or recognize when it is time to eat. Your healthcare team should examine these possible causes before using cannabis for appetite. Treating mouth pain, improving food texture, adjusting medications, or creating a quieter eating environment may produce meaningful improvement. Medical cannabis may become a reasonable option when poor appetite continues, and weight loss affects your strength, comfort, or recovery. A clear evaluation helps your clinician determine whether appetite stimulation is likely to be effective and whether you can eat safely after the dose.

18.2 When Appetite Stimulation May Be Considered

A supervised cannabis trial may be considered when you consistently eat too little, lose weight, or experience distress around meals despite appropriate support. It may also fit comfort-focused care when enjoying food and maintaining pleasure become more important than meeting strict nutritional targets. THC can increase appetite in some patients, but the amount should remain low enough to preserve alertness and swallowing ability. The timing should allow the effect to appear before a meal rather than after the opportunity to eat has passed. Your clinician should also consider your food preferences and daily rhythm. Familiar meals, smaller portions, favorite flavors, and simple finger foods may work well alongside cannabis. This combined approach can make eating feel more comfortable and inviting without relying on medication alone.

18.3 Measuring Meaningful Nutritional Benefit

The goal of appetite treatment is not simply to make you say that you feel hungry. Your care team should look for practical improvements in food intake, hydration, weight stability, energy, and comfort during meals. Record how much of each meal you finish, whether you accept favorite foods, and whether nausea or distress decreases. Also watch for coughing, prolonged chewing, food remaining in the mouth, or excessive sleepiness during meals. These signs may indicate swallowing difficulty that requires professional assessment. A successful cannabis trial may help you eat more willingly, remain comfortable at the table, or maintain your weight. If appetite improves but dizziness, confusion, or unsafe swallowing appears, the dose or timing should be adjusted. Regular review helps preserve the nutritional benefit while protecting your safety and ability to enjoy meals.

19. Medical Cannabis for Nausea and Treatment-Related Symptoms

19.1 Identifying the Source of Nausea

Nausea in dementia can come from many causes, so identifying the source is the first step toward effective treatment. Common causes include constipation, reflux, infection, dehydration, migraine, gastrointestinal disease, medication side effects, and cancer treatment. Anxiety, pain, and long periods without food may also contribute. Your clinician should review when the nausea begins, what makes it worse, and whether vomiting, abdominal pain, fever, or weight loss is present. A medication review is especially important because antibiotics, pain medicines, dementia drugs, and several other treatments may upset the stomach. Medical cannabis may help manage persistent nausea in selected patients, particularly when standard measures have not provided enough relief. A clearly identified cause allows your clinician to decide whether cannabis should supplement other treatment or whether another medical problem needs attention first.

19.2 Selecting a Route That Fits the Clinical Situation

The best route of administration depends on how quickly relief is needed and whether you can swallow safely. Oral oils, capsules, and edibles may provide longer-lasting effects, but they usually take longer to work. This delay makes careful timing and patience especially important. Your clinician may consider:

• Your ability to swallow liquids, capsules, or food safely
• How quickly the nausea usually develops
• How long symptom relief needs to last
• Whether vomiting prevents oral medicine from staying down
• Your ability to cooperate with sublingual or inhaled administration
• The risk of coughing, choking, or aspiration
• The amount of supervision available after dosing

A route should be simple, measurable, and practical for your level of function. Your clinician may also time the dose before meals, medications, or treatments when nausea follows a predictable pattern.

19.3 Recognizing When More Cannabis Could Worsen Vomiting

Cannabis can relieve nausea for some patients, but frequent or heavy use may occasionally contribute to repeated vomiting. Cannabis hyperemesis syndrome can cause severe nausea, recurring vomiting, abdominal discomfort, dehydration, and temporary relief from hot showers or baths. This condition is less likely during a low-dose, supervised trial, but it should still be recognized. Repeated vomiting should not automatically lead to a larger cannabis dose because more exposure may worsen the problem if cannabis itself is contributing. Tell your clinician about every cannabis product you use, including products taken outside the treatment plan. Prompt reassessment allows your healthcare team to check for dehydration, infection, medication effects, or gastrointestinal illness. If cannabis is involved, reducing or pausing treatment may help while your clinician considers safer symptom control options.

20. Dementia Related Hallucinations and Psychosis

20.1 Understanding Hallucinations Across Dementia Types

Hallucinations involve seeing, hearing, or sensing something that is not present. They can occur in several dementia disorders, but vivid visual hallucinations are especially common in Lewy body dementia. You may see people, animals, shapes, or movement that others do not see. Not every unusual perception is a true hallucination. Poor lighting, mirrors, shadows, hearing loss, and vision problems can cause illusions or misinterpretations. Dementia may also lead to delusions, such as believing that someone is stealing possessions or that a familiar person has been replaced. Your healthcare team should record what you experience, how often it happens, and whether it causes fear or unsafe behavior. Some hallucinations are calm and do not require medication. Others may signal pain, illness, medication effects, or delirium and need closer evaluation.

20.2 Why THC Requires Extra Caution

THC changes perception, attention, memory, and emotional response. In a patient who already experiences hallucinations, suspiciousness, or difficulty recognizing surroundings, a dose that is too strong may intensify confusion or fear. This does not mean every patient with dementia must avoid THC. A very small amount may still be considered for severe pain, nausea, appetite loss, or distress when the possible benefit is meaningful. Product selection and dose size should reflect your hallucination history and sensitivity to psychoactive medicines. A CBD-dominant product or a formulation with minimal THC may be more suitable when altered perception is a concern. After each dose, your care team should observe your facial expression, communication, alertness, and response to familiar people. Any increase in fear, paranoia, or visual disturbance should prompt a dose review.

20.3 When Hallucinations Require Urgent Evaluation

Hallucinations require prompt medical attention when they appear suddenly, become much more intense, or occur with other signs of illness. A rapid change may indicate delirium, infection, dehydration, medication toxicity, stroke, or another acute condition rather than progression of dementia. Seek urgent evaluation when hallucinations occur with fever, reduced alertness, repeated falls, severe agitation, weakness, speech changes, or dangerous behavior. A recent medication or cannabis dose change should also be reported. Do not respond to sudden hallucinations by automatically giving more cannabis or another sedating medicine. Your clinician should first identify the cause and protect you from injury. Once the urgent problem is treated, the medical cannabis plan can be reviewed and restarted cautiously when appropriate.

21. Special Considerations for Lewy Body Dementia

21.1 Fluctuating Attention and Alertness

Lewy body dementia often causes noticeable changes in attention and alertness throughout the day. You may appear fully engaged at one moment and then become unusually drowsy, confused, or slow to respond later. These shifts can happen even when no medication has changed. Because alertness already fluctuates, your healthcare team needs a clear baseline before medical cannabis begins. Record the times when you are usually most awake, when staring or drowsiness tends to appear, and whether sleep, meals, pain, or activity affect these patterns. Cannabis effects should be compared with your usual fluctuations rather than judged by a single observation. A well-timed, low dose trial may still support pain, appetite, sleep, or distress. Careful records help your clinician separate a helpful treatment effect from the natural changes associated with Lewy body dementia.

21.2 Hallucinations and Medication Sensitivity

Visual hallucinations are common in Lewy body dementia. You may see people, animals, objects, or movement that others cannot see. Some experiences may feel neutral, while others can cause fear, suspicion, or unsafe behavior. People with Lewy body dementia may also respond strongly to psychoactive medicines. THC can affect perception, attention, and emotional response, so a high dose may intensify hallucinations or confusion. This makes conservative product selection especially important. Your clinician may favor a CBD-dominant product or a formulation containing only a very small amount of THC. The first doses should be given in a familiar setting with close observation. A carefully selected cannabis plan may still help with pain, nausea, appetite loss, or sleep while limiting unwanted changes in perception.

21.3 Movement, Blood Pressure, and Fall Risk

Lewy body dementia may cause slow walking, rigidity, freezing of gait, poor balance, and dizziness when standing. These symptoms already increase fall risk, and THC may add temporary sleepiness, slower reactions, or blood pressure changes. Before treatment begins, your team should review:

• Previous falls and near falls
• Dizziness when standing
• Use of a cane, walker, or wheelchair
• Blood pressure medicines
• Assistance needed for transfers and toileting
• Times of day when movement is most difficult

After each dose, you may need help standing, walking, bathing, or using the bathroom. This support allows medical cannabis to be tested without unnecessary injury. If comfort improves but movement becomes less stable, your clinician can adjust the dose, timing, or product while continuing to pursue symptom relief.

22. Special Considerations for Frontotemporal Dementia

22.1 Behavioral and Personality Changes

Frontotemporal dementia often affects behavior, personality, judgment, and social awareness before memory becomes severely impaired. You may act impulsively, lose interest in familiar activities, repeat the same action, eat compulsively, or say things that do not match your previous personality. These changes can make cannabis treatment harder to assess because reduced inhibition may be mistaken for improved mood. Your care team should define the specific symptom being treated, such as pain, anxiety, sleep disruption, or severe repetitive behavior. Medical cannabis should not be expected to restore judgment or personality. However, a supervised trial may support comfort when a clear symptom remains troublesome. Objective observations help determine whether you appear calmer and more comfortable without becoming more impulsive, withdrawn, or confused.

22.2 Language and Communication Variants

Some forms of frontotemporal dementia mainly affect language. You may struggle to find words, name objects, understand sentences, follow instructions, or explain internal symptoms. These difficulties can make it challenging to describe pain, dizziness, nausea, or intoxication. Your healthcare team should use simple questions and observe nonverbal responses. Facial expression, movement, posture, resistance, appetite, and sleep may provide more reliable information than broad questions about how you feel. A cannabis trial should begin with a symptom that can be observed clearly. For example, your team may track grimacing during movement, repeated nighttime waking, or reduced meal intake. This approach allows treatment to be evaluated even when verbal communication is limited.

22.3 Monitoring Cannabis When Insight Is Limited

Frontotemporal dementia may reduce insight, impulse control, and awareness of consequences. You may forget that you already took a dose, seek additional cannabis, or use more than instructed because the product is accessible. Structured administration protects you while preserving treatment as an option. One responsible person should measure each dose, record the time, secure the product, and monitor your response. Edibles should be kept separate from ordinary snacks because compulsive eating can increase the risk of accidental exposure. Financial safeguards may also be needed if you can purchase products independently without understanding cost or dosing limits. Clear routines and secure storage allow your clinician to test medical cannabis carefully while reducing repeated dosing, product confusion, and preventable side effects.

23. Special Considerations for Vascular Dementia

23.1 Stroke History and Cognitive Pattern

Vascular dementia develops when reduced blood flow damages areas of your brain. This damage may follow one major stroke, several smaller strokes, or long-term blood vessel disease. Your symptoms can include slower thinking, difficulty planning, reduced concentration, emotional changes, and trouble organizing familiar tasks. Some people experience a stepwise pattern, with a noticeable decline after a vascular event followed by a period of relative stability. Others have gradual changes that overlap with Alzheimer’s disease. Walking problems, weakness, poor balance, or reduced coordination may appear alongside cognitive symptoms. Before beginning medical cannabis, your clinician should review your stroke history and usual thinking pattern. This baseline helps determine whether later changes relate to cannabis, another vascular event, or the normal course of your condition. A carefully supervised trial may still support pain, appetite, sleep, or distress when your cardiovascular and mobility needs are considered.

23.2 Cardiovascular and Blood Pressure Concerns

THC may temporarily affect heart rate and blood pressure. You may feel dizzy, lightheaded, or unsteady when standing, especially if you already take blood pressure medicine or have circulation problems. These effects are often manageable through conservative dosing and close observation. Your clinician may review:

• Your usual sitting and standing blood pressure
• Previous fainting or dizziness
• Heart rhythm problems
• Current heart and blood pressure medicines
• Stroke prevention medicines
• Your fall history and walking ability
• The time of day when symptoms are most noticeable

The first doses should be given when you can remain seated and supervised. Standing slowly, using your mobility aid, and getting help with bathroom trips can reduce the risk of injury. If a product helps your target symptom but causes dizziness, your clinician can adjust the amount, timing, cannabinoid ratio, or route.

23.3 Recognizing a New Stroke

A new stroke requires immediate medical care. Cannabis should never be used to explain or treat sudden weakness, facial drooping, speech difficulty, vision loss, severe imbalance, or abrupt confusion. These symptoms differ from the gradual cognitive changes usually associated with dementia. You may not be able to describe what is happening clearly, so the people around you should watch for sudden changes in movement, speech, facial symmetry, coordination, or alertness. The time when symptoms began should be recorded because rapid treatment may protect brain function. After emergency assessment, tell the medical team about your cannabis product, dose, and timing. This information helps clinicians interpret your symptoms accurately. Once your condition is stable, your supervising clinician can decide whether the cannabis plan should continue or be adjusted.

24. Special Considerations for Parkinson’s Disease Dementia

24.1 Movement Symptoms and Mobility

Parkinson’s disease dementia may occur alongside tremor, rigidity, slow movement, freezing, and postural instability. These symptoms can make standing, turning, walking, and transferring more difficult. Medical cannabis may still be considered for pain, sleep disruption, nausea, or distress, but mobility should be monitored closely. A dose that causes excessive sleepiness or dizziness may make movement less reliable. Your care team should observe whether you walk more comfortably, move with less stiffness, or tolerate daily care more easily after treatment. They should also watch for slower reactions, increased freezing, or a greater need for physical assistance. The goal is to improve comfort without reducing safe movement. Starting with a very low dose and giving it when supervision is available allows your clinician to assess the balance between symptom relief and mobility.

24.2 Medication Timing and Symptom Fluctuation

Parkinson’s medicines often produce periods known as on and off times. During an on period, movement may be easier. During an off period, stiffness, slowness, tremor, or freezing may become more noticeable. These changes can make cannabis effects difficult to interpret. Your cannabis journal should record the timing of levodopa and other Parkinson’s medicines alongside every cannabis dose. Note whether movement, alertness, hallucinations, blood pressure, or sleepiness changed before or after each treatment. Keeping the medication and cannabis schedule stable helps your clinician identify patterns. Medical cannabis should not replace prescribed Parkinson’s treatment or prompt unsupervised medication changes. Coordinated timing may allow you to pursue symptom relief while preserving the benefits of your established neurological care.

24.3 Sleep and REM Sleep Behavior Symptoms

Parkinson’s disease dementia can involve vivid dreams, dream enactment, shouting, kicking, nighttime movement, and severe daytime sleepiness. These symptoms may reflect REM sleep behavior disorder or another sleep condition rather than simple insomnia. A nighttime cannabis product may help with pain, anxiety, or difficulty settling, but sedation alone may not address the underlying sleep disorder. Your clinician should ask about falls from bed, injuries, breathing pauses, repeated waking, and how alert you feel during the day. Track whether cannabis improves sleep continuity and morning comfort without increasing confusion or daytime drowsiness. Bedroom safety measures and specialist sleep evaluation may also be needed. A coordinated approach can support more restful nights while protecting movement, breathing, and daytime participation.

25. Special Considerations for Mixed Dementia

25.1 Recognizing Overlapping Causes

Mixed dementia means that more than one type of brain disease contributes to your symptoms. Alzheimer’s changes may occur together with vascular damage, Lewy body disease, or another neurological condition. This overlap can create a combination of memory loss, slowed thinking, movement changes, hallucinations, mood symptoms, or problems with judgment. Because several conditions may be present, your symptoms may not follow one predictable pattern. You may show gradual memory decline, with sudden changes after a stroke, or periods of fluctuating alertness. These differences matter when your clinician considers medical cannabis. Your treatment plan should focus on the symptoms that affect you most, such as pain, poor sleep, appetite loss, nausea, or distress. A clear symptom target helps your healthcare team judge whether cannabis provides useful relief even when the underlying diagnosis includes several overlapping disorders.

25.2 Prioritizing the Most Safety-Relevant Features

When several types of dementia overlap, the most important treatment decisions often depend on your current symptoms rather than the diagnostic label alone. Your clinician should identify the features that most strongly affect dosing, product selection, and supervision. Important factors may include:

• Hallucinations or severe sensitivity to psychoactive medicines
• Frequent falls, freezing, or poor balance
• Stroke history or unstable blood pressure
• Impulsive behavior or repeated dosing risk
• Swallowing difficulty
• Severe daytime sleepiness
• Complex medication use
• Limited ability to report side effects

These concerns do not automatically prevent medical cannabis treatment. They help your clinician choose a more suitable route, lower starting dose, or CBD-dominant product. Clear observation and written records also make it easier to adjust the plan without abandoning a potentially helpful treatment.

25.3 Building a Flexible Treatment Plan

Mixed dementia can change over time, so your cannabis plan should remain flexible. The symptom that matters most today may not remain the main concern later. Pain, appetite, sleep, mobility, communication, and behavior may each require different attention as the condition progresses. Your clinician should regularly review the product, dose, route, and treatment goal. A product that works well while you can swallow independently may need to change if swallowing becomes difficult. A daytime dose may also require adjustment if alertness or balance declines. Flexibility does not mean changing several things at once. Each adjustment should be small and clearly documented. This approach helps you continue pursuing comfort while adapting the treatment plan to your changing abilities and priorities.

26. THC, CBD, and Balanced Formulations

26.1 When a CBD Dominant Product May Be Preferred

A CBD-dominant product may be considered when your treatment team wants to limit intoxication while still exploring possible symptom relief. This approach may be especially useful during the day or when you have a history of hallucinations, anxiety, falls, or strong sensitivity to psychoactive medicines. CBD does not usually cause the same noticeable intoxication as THC, but it can still affect your body. You may experience fatigue, digestive changes, changes in appetite, or medication interactions. Your clinician or pharmacist should review your full medication list before treatment begins. A CBD-dominant product may fit goals involving discomfort, anxiety, or sleep support, but results vary. Starting with a measurable product and tracking your response helps determine whether CBD provides enough benefit on its own or whether a very small amount of THC should later be considered.

26.2 When a Small Amount of THC May Be Considered

A small amount of THC may be considered when symptoms such as persistent pain, poor appetite, nausea, severe distress, or sleep disruption remain difficult to manage. THC may produce more noticeable effects than CBD, so the potential benefit should align with a clearly defined treatment need. Your clinician should begin with a very low dose and allow enough time to observe the full effect. The first doses should be given in a calm, familiar setting, with help available for walking, eating, and personal care. The goal is not to create strong intoxication. It is to find the smallest amount that supports comfort or function without causing unnecessary confusion, anxiety, or physical slowing. When the target symptom improves, the dose should remain stable rather than continuing to increase.

26.3 Why Balanced Products Are Not Automatically Mild

A balanced product contains both THC and CBD, but this does not mean the product will feel mild. The actual effect depends on the amount of THC in each dose, your sensitivity, your previous cannabis experience, and how the product is taken. CBD may soften some THC effects for certain patients, but it does not cancel intoxication. A balanced edible or oil can still cause sleepiness, dizziness, altered perception, or confusion, especially in an older adult who has never used cannabis. Read the label for the exact amount of THC and CBD in each dose rather than relying on words such as balanced or gentle. Your clinician should treat the THC content seriously and begin conservatively. Careful measurement allows balanced products to be considered safely without assuming they are weaker than they really are.

27. Choosing an Administration Route

27.1 Oral Oils, Capsules, and Edibles

Oral cannabis products may provide longer-lasting effects, which can be useful when you need steady relief from pain, nausea, poor appetite, or nighttime symptoms. Oils, capsules, and edibles are also easier to measure than smoked cannabis when the label clearly states the amount of THC and CBD in each serving. These products usually take longer to work because they must pass through your digestive system. You may not notice the full effect for one to several hours, and the response can last much longer than expected. Food intake, digestion, body weight, and other medications may also affect how strongly the dose feels. The greatest dosing mistake is taking more before the first amount has reached its full effect. Your written plan should state the exact dose and waiting period. One responsible person should record each dose so you do not accidentally receive another serving too soon.

27.2 Sublingual and Buccal Products

Sublingual products are placed under your tongue, while buccal products are placed between your cheek and gum. Some of the cannabinoids may be absorbed through the tissues in your mouth, which can produce effects sooner than a swallowed capsule or edible. Successful administration requires you to hold the product in place for the recommended period. Dementia may make this instruction difficult to remember, and you may swallow the liquid immediately. Swallowing does not necessarily make the dose ineffective, but it can delay the onset and lengthen the effects. Your care team should use the same technique each time to keep the response predictable. The dispenser must also measure the liquid carefully because droppers may hold different volumes. A clearly marked device, written dose, and a consistent administrator can make this route practical when swallowing remains safe.

27.3 Inhaled and Topical Products

Inhaled cannabis usually acts quickly, but it may not be the most reliable route when dementia affects coordination, understanding, or breathing. Smoking can expose your lungs to irritants, while vapor devices require correct handling and may deliver inconsistent amounts if your inhalation changes. Your clinician may consider:

• Whether you can operate the device correctly
• Whether you have asthma, lung disease, or frequent coughing
• Whether rapid symptom relief is necessary
• Whether a measured inhaled dose is available
• Whether another person can supervise the administration
• Whether facility or housing policies allow inhaled products

Topical products are applied to the skin and may help localized discomfort without causing strong whole-body effects. Transdermal products differ in that they are designed to deliver cannabinoids into the bloodstream. Your clinician should confirm which type you are using and whether its effects match your treatment goal.

28. Selecting a Product the Patient Can Use Reliably

28.1 Prioritizing Measurable Cannabinoid Content

A reliable medical cannabis product should clearly state how much THC and CBD you receive in each dose. This information allows your clinician to start conservatively, compare results, and make small adjustments when needed. Strain names alone do not provide sufficient dosing information because products with similar names may contain very different amounts of cannabinoids. Look for labels that state milligrams per capsule, gummy, milliliter, spray, or measured inhalation. Your treatment record should include the exact product name, cannabinoid ratio, serving size, and amount actually given. Measurable content also helps prevent confusion when you purchase a replacement. Even products with similar packaging may contain a different concentration. Check every new label before continuing the previous volume or portion, and ask your clinician or pharmacist to confirm the dose when the formulation changes.

28.2 Avoiding Complex Product Rotations

Using several products at the same time makes it difficult to understand what is helping. Rotating between gummies, oils, flower, capsules, and concentrates can produce different onset times, durations, and levels of intoxication. Homemade or poorly labeled products create even more uncertainty. Begin with one product, one route, one schedule, and one primary symptom goal. Keep these factors stable long enough to observe changes in comfort, appetite, sleep, movement, and alertness. When the response is unclear, your clinician can adjust one part of the plan rather than replacing everything at once. A simple plan also reduces medication errors. You and the people assisting you can quickly recognize the correct product, follow the same instructions, and accurately document each dose. Simplicity supports safer treatment without limiting your ability to explore another formulation later if the first one does not meet your needs.

28.3 Considering Swallowing, Vision, and Hand Function

The best product is one you can take safely and consistently. A capsule may seem convenient, but it may not fit if you have swallowing difficulty. A liquid may provide precise dosing, but measuring it can become challenging if your vision or hand control is limited. Your clinician should consider whether you can read the label, open the package, hold a dropper, divide an edible, operate a device, and remember the administration steps. Child-resistant packaging may also be difficult to open, which can increase frustration or encourage unsafe storage. Needing assistance does not prevent you from using medical cannabis. A designated administrator can measure the dose, explain what you are receiving, and record the response. Matching the product to your abilities helps preserve your participation while reducing spills, repeated doses, choking risks, and inconsistent treatment.

29. Starting With a Very Low Dose

29.1 Why Dementia Often Requires Extra-Conservative Dosing

Dementia can change how your brain and body respond to cannabis. Older age, lower body weight, neurological disease, slower metabolism, and several prescription medicines may make a small amount feel stronger or last longer than expected. You may also find it difficult to describe early side effects such as dizziness, altered perception, or mental slowing. Starting with a very low dose gives your clinician time to understand your individual response. The first amount may be smaller than doses commonly used by younger adults or experienced cannabis patients. This cautious beginning does not reduce the value of treatment. It helps identify the lowest amount that can relieve pain, improve appetite, reduce nausea, or support sleep while protecting your daily function. Your dose can be gradually increased once the initial dose is well tolerated but does not provide sufficient relief. Slow adjustment produces clearer information and reduces the chance that temporary confusion or sleepiness will interfere with a fair evaluation of the treatment.

29.2 Giving the First Dose in a Calm, Familiar Setting

Your first cannabis dose should be given in a place where you feel comfortable and recognize the people around you. A familiar environment reduces anxiety and makes it easier for your care team to notice changes in alertness, movement, communication, or mood. The first dose should not be scheduled before appointments, bathing, visitors, travel, or demanding activities. Your care team should also reduce noise and avoid asking you to complete unfamiliar tasks. Keeping the day simple allows the cannabis response to become the main change being observed. A trusted person should remain nearby during the expected period of effect. This person can assist with standing, walking, eating, or using the bathroom. They should record when the dose was given, what you ate, how you behaved, and whether your target symptom improved. Careful observation helps your clinician decide whether the same dose should be repeated.

29.3 Waiting Long Enough Before Redosing

Cannabis products do not all begin working at the same speed. Inhaled products may act within minutes, while swallowed oils, capsules, and edibles may take much longer. An oral dose can continue to become stronger for several hours, especially when digestion is slow. Taking another dose too early can cause the amounts to overlap. This may lead to excessive sleepiness, dizziness, confusion, anxiety, or poor coordination. A delayed effect should not automatically be treated as a failure. Your written plan should state:

• The exact starting amount
• The time the dose was given
• The expected onset period
• The minimum waiting period
• Who may approve another dose
• What effects should be recorded
• When your clinician should be contacted

Following the waiting period protects you from accidental overconsumption. It also gives your healthcare team a more accurate picture of how one measured dose affects your symptoms and function.

30. Titrating One Variable at a Time

30.1 Keeping the Product and Route Stable

Titration means adjusting your cannabis dose gradually until you reach useful symptom relief. During this process, the product and the route of administration should remain stable whenever possible. Changing the brand, cannabinoid ratio, route, dose, and timing together makes it nearly impossible to identify what caused the result. Use the same labeled product and measurement method for each scheduled dose. An oil, edible, capsule, or inhaled product may produce different onset times and durations even when the stated THC amount appears similar. Consistency helps your clinician compare one day with another. If the product must change because it becomes unavailable, check the new THC and CBD content before using it. Do not assume that the same volume, portion, or number of drops provides the same dose. Your clinician or pharmacist can help calculate a suitable starting amount for the replacement.

30.2 Making Small, Infrequent Adjustments

Dose changes should be small enough for your care team to recognize both benefit and side effects. After an adjustment, allow enough observation time to assess your alertness, appetite, sleep, movement, behavior, and primary treatment target. Increasing the amount every day may cause effects to accumulate before your response is fully understood. This is especially important with oral products, which may remain active for many hours. Your clinician may recommend maintaining the same amount across several doses or days before considering another change. Only one part of the plan should change at a time. For example, your clinician may adjust the dose while keeping the product, route, and schedule unchanged. This method produces reliable information and helps prevent unnecessary increases when another factor, such as pain treatment or an improved sleep routine, caused the improvement.

30.3 Stopping Dose Escalation When Benefit Appears

The best cannabis dose is the smallest amount that provides meaningful relief with acceptable side effects. Once your target symptom improves, continuing to increase the dose may add intoxication without producing greater benefit. Improvement may mean eating more of your meals, waking less often, showing fewer pain behaviors, or experiencing less distress during care. Your clinician should compare these changes with your baseline rather than looking for a dramatic response. Greater sleepiness does not necessarily mean that cannabis is working better. A dose may be too strong if you become less communicative, less steady, or unable to participate in meals and activities. Maintaining the minimum effective dose supports comfort while preserving alertness, mobility, and independence. Regular follow-up can confirm whether the benefit continues or whether a later adjustment becomes necessary.

31. Recognizing That the Dose Is Too High

31.1 Cognitive and Behavioral Warning Signs

A cannabis dose may be too high when changes in thinking or behavior become more noticeable than the intended symptom relief. You may appear suddenly more confused, unusually quiet, fearful, suspicious, or unable to follow familiar instructions. Speech may become disorganized, and you may have difficulty recognizing people, rooms, or routines that are usually familiar. Other warning signs include panic, paranoia, hallucinations, reduced communication, repeated questions, or withdrawal from normal interaction. These effects may be especially difficult to identify when dementia already affects memory or judgment, which is why your care team should compare your response with a written baseline. A strong reaction does not mean medical cannabis is unsuitable for you. It often means the dose, product, or timing needs adjustment. Reducing the amount or choosing a product with less THC may allow you to continue pursuing symptom relief with greater comfort and clarity.

31.2 Physical Warning Signs

Physical signs of excessive dosing may appear alongside confusion or may occur on their own. You may become very sleepy, dizzy, unsteady, or unable to stand safely. Slurred speech, poor coordination, low blood pressure, vomiting, reduced appetite, and difficulty drinking enough fluid may also occur. Your care team should watch for:

• Difficulty waking you normally
• New trouble standing or walking
• Repeated dizziness or faintness
• Slurred or unusually slow speech
• Vomiting or refusal of food and fluids
• Marked weakness or poor coordination
• A sudden increase in falls or near falls

These effects are more likely when THC is combined with sedating medicines, alcohol, or another cannabis product. Recording the exact product, amount, and time of use helps your clinician identify what caused the reaction and how the plan should change.

31.3 What to Do After Excessive Dosing

Do not give additional cannabis when you suspect the dose was too high. Keep the patient in a calm, familiar setting and provide close supervision. Prevent walking, driving, bathing alone, or using stairs until balance and alertness return to the usual baseline. Check the product label, dose amount, and administration record. Determine whether an extra dose, stronger product, or unexpected timing change occurred. Offer fluids only when the patient is fully alert and can swallow safely. Contact the supervising clinician for guidance when symptoms are significant or persistent. Emergency help is appropriate for chest pain, severe breathing difficulty, seizure, serious injury, unresponsiveness, or sudden neurological changes. Once the reaction resolves, treatment may continue at a lower dose or with a different formulation under clinical supervision.

32. Cannabis and Dementia Medications

32.1 Cholinesterase Inhibitors

Donepezil, rivastigmine, and galantamine are commonly prescribed to support memory and thinking in certain dementia disorders. These medicines may cause nausea, loss of appetite, dizziness, fainting, changes in sleep, or a slow heart rate in some patients. Cannabis can produce some overlapping effects, particularly dizziness, nausea, appetite changes, and altered alertness. When both treatments are used, it may become difficult to determine which one caused a new symptom unless the medication schedule and cannabis doses are recorded carefully. Your clinician should review heart rate, blood pressure, appetite, sleep, and recent falls before starting cannabis. A low dose and stable schedule can help separate treatment effects. Medical cannabis should complement your dementia care rather than replace medicines that your specialist believes are still providing benefit.

32.2 Memantine and Cognitive Symptoms

Memantine may be prescribed for moderate or advanced Alzheimer’s disease and certain other dementia conditions. Possible side effects include dizziness, confusion, headache, and constipation. These symptoms can resemble cannabis effects, especially during the early stages of treatment or after a dose adjustment. Your healthcare team should avoid changing memantine and cannabis at the same time whenever possible. Keeping one treatment stable allows your clinician to understand whether changes in alertness, behavior, balance, or bowel function relate to the new cannabis plan. A written record should include the timing of both medicines, your usual cognitive pattern, and any changes in daily function. This careful comparison supports safer decisions and allows medical cannabis to be evaluated fairly without disrupting an established dementia treatment unnecessarily.

32.3 Newer Disease-Modifying Treatments

Some patients with early Alzheimer’s disease may receive newer treatments designed to affect the underlying disease process. These therapies may require specialist supervision, repeated infusions, brain imaging, laboratory monitoring, and careful review of bleeding or swelling risks. Medical cannabis does not replace these treatments or their monitoring requirements. It may still be considered separately for symptoms such as pain, nausea, poor appetite, anxiety, or sleep disruption when your clinician believes the possible benefit is appropriate. Every member of your healthcare team should know which cannabis products you use. This includes your neurologist, primary care clinician, pharmacist, infusion team, and cannabis clinician. Coordinated care helps prevent medication confusion, supports accurate symptom tracking, and allows medical cannabis to remain part of a broader treatment plan focused on both comfort and established neurological care.

33. Cannabis and Psychiatric or Behavioral Medications

33.1 Antidepressants and Anxiety Medicines

Antidepressants and anxiety medicines may be prescribed to reduce depression, fear, irritability, panic, or persistent emotional distress. Some of these medicines can cause dizziness, sleepiness, nausea, changes in appetite, or changes in blood pressure. Cannabis may produce similar effects, so combining them requires careful observation. Your clinician should review which medications you take, when you take them, and whether the doses have changed recently. Starting cannabis while another psychiatric medicine is being adjusted can make it difficult to identify which treatment caused a new benefit or side effect. Medical cannabis may still fit your care plan when anxiety, pain, poor sleep, or appetite loss remains troublesome. A low starting dose and stable medication schedule help your healthcare team assess the combination more accurately. Report increased confusion, unusual restlessness, marked sleepiness, or changes in mood so the plan can be refined promptly.

33.2 Antipsychotic Medications

Antipsychotic medicines may be prescribed when hallucinations, delusions, severe agitation, or aggression cause significant distress or danger. These medicines require careful monitoring in dementia because they can affect alertness, movement, blood pressure, and balance. Adding cannabis introduces another substance that can influence perception and behavior. THC may increase confusion, suspiciousness, or hallucinations in some patients, while both treatments may contribute to drowsiness or physical slowing. Your prescribers should coordinate before cannabis is introduced. Your healthcare team should track:

• The behavior or symptom each treatment is intended to address
• The timing of every antipsychotic and cannabis dose
• Changes in hallucinations, fear, agitation, or communication
• Walking, stiffness, tremor, and balance
• Daytime alertness and participation
• Falls, near falls, and blood pressure-related dizziness

Clear records help determine whether cannabis adds useful symptom relief or creates overlapping effects. Do not reduce or stop an antipsychotic without medical guidance.

33.3 Benzodiazepines and Sleep Medicines

Benzodiazepines and prescription sleep medicines may reduce anxiety or help with short-term insomnia, but they can also cause drowsiness, confusion, poor balance, and slower reactions. These effects may become stronger when combined with THC or another sedating cannabis product. The combination may make it harder for you to stand safely, communicate discomfort, recognize illness, or wake normally during the night. Risk can be greater when you already have limited mobility, low blood pressure, swallowing problems, or a history of falls. A clinician-supervised cannabis plan may allow your treatment team to review whether all sedating medicines remain necessary. However, benzodiazepines should not be stopped suddenly because withdrawal can cause serious symptoms. Any reduction should follow a structured medical plan. The goal is to support sleep or anxiety relief while preserving daytime alertness, safe movement, and your ability to participate in daily care.

34. Cannabis and Common Older Adult Medications

34.1 Blood Thinners and Cardiovascular Drugs

Many people with dementia also take medicines for blood pressure, heart rhythm problems, stroke prevention, or blood clot risk. These may include anticoagulants, antiplatelet medicines, and various cardiovascular treatments. Cannabis can affect blood pressure, heart rate, and the way the liver processes certain medicines. CBD may interact with some drugs by changing how quickly they are broken down, while THC may contribute to dizziness or a faster heart rate. The clinical importance depends on the product, dose, and medicine involved. Your pharmacist should review the full treatment list before cannabis begins. Monitoring may include blood pressure, bruising, bleeding, dizziness, heart symptoms, and laboratory tests when appropriate. This review helps your team select a cannabis product that supports symptom relief while respecting your cardiovascular treatment.

34.2 Opioids, Gabapentinoids, and Muscle Relaxants

Opioids, gabapentinoids, and muscle relaxants may be prescribed for persistent pain, nerve pain, muscle spasms, or severe physical discomfort. These medicines can cause sleepiness, poor coordination, constipation, and slower responses. Cannabis may add to these effects, particularly when the product contains THC. Medical cannabis may still be considered as part of a pain management plan. Some patients may find greater comfort with a carefully selected combination, but each medicine should have a clear purpose. Your clinician should monitor whether pain improves without excessive sedation or loss of mobility. Do not change prescribed pain medicines independently after starting cannabis. Sudden opioid changes can cause withdrawal or uncontrolled pain. A written record of pain behaviors, alertness, bowel function, walking, and daily participation helps your healthcare team decide whether later medication adjustments are appropriate.

34.3 Diabetes and Other Long-Term Treatments

Diabetes medicines, thyroid treatments, seizure medicines, and other long-term therapies often depend on consistent timing, food intake, hydration, and accurate administration. Dementia can already make these routines difficult, and cannabis related appetite or alertness changes may affect them further. For example, increased appetite may change meal size or timing, while nausea or sleepiness may reduce food intake. These changes matter when you take insulin or another medicine that can lower blood sugar. Dizziness may also come from low blood sugar, dehydration, blood pressure changes, or cannabis, so careful observation is necessary. Keep one updated list of prescriptions, nonprescription products, supplements, and cannabis products. Every clinician and pharmacist involved in your care should receive the same information. Coordinated medication review helps prevent missed doses, overlapping side effects, and avoidable confusion while allowing medical cannabis to remain a carefully managed part of your treatment plan.

35. Preventing Falls and Mobility Injuries

35.1 Assessing Baseline Fall Risk

Before you begin medical cannabis, your healthcare team should understand how safely you already move through your home or care setting. Dementia can affect judgment, depth perception, coordination, and the ability to remember safety instructions. Arthritis, muscle weakness, poor vision, low blood pressure, and neurological disease may add further risk. Your clinician should review previous falls, near falls, dizziness, nighttime bathroom trips, and changes in walking speed. Footwear, mobility aids, vision, and sedating medicines should also be considered. This baseline helps your care team recognize whether a later change comes from cannabis or from an existing mobility problem. A fall risk assessment does not mean medical cannabis should be avoided. It gives your team the information needed to choose a lower starting dose, safer timing, and suitable supervision. These steps help you explore symptom relief while preserving your ability to move with confidence.

35.2 Supervising Movement After a Dose

THC may temporarily affect balance, reaction time, coordination, and blood pressure. The period of strongest effect depends on the product and route, so your treatment plan should identify when extra help may be needed. After a dose, support may include:

• Helping you stand slowly from a bed or chair
• Staying nearby during walking and transfers
• Assisting with bathing, stairs, and bathroom use
• Making sure your cane or walker is within reach
• Avoiding unnecessary walking during peak effects
• Watching for dizziness, weakness, or unusual sleepiness

Supervision should support your independence rather than remove it. You may still complete familiar activities with the right assistance. If your target symptom improves but your movement becomes less stable, your clinician can adjust the dose, timing, or THC content.

35.3 Adapting the Home Environment

A safer environment reduces fall risk whether or not you use medical cannabis. Clear walking paths, steady lighting, secure rugs, and stable furniture make movement easier when attention or balance changes. Grab bars near the toilet and shower, accessible seating, and appropriate mobility devices can provide additional support. Nightlights may help you recognize the bathroom and avoid shadows that increase confusion. Frequently used items should remain within easy reach so you do not need to climb or stretch. These changes allow medical cannabis to remain part of your symptom management plan without relying only on supervision. A supportive environment, low dosing, and careful observation work together to protect comfort, mobility, and daily participation.

36. Protecting Against Medication Errors

36.1 Preventing Forgotten or Repeated Doses

Dementia may make it difficult to remember whether a cannabis dose has already been taken. Repeated dosing is especially concerning with oral products because the first dose may still be developing when another is given. Use one clear administration system. This may include a written log, a locked dispenser, an alarm, a marked calendar, or direct supervision. Each entry should record the product, dose, time, route, and person who administered it. The system should match your abilities. You may remain capable of self-administration during early dementia but need reminders or confirmation. As memory changes, another person may need to measure and record every dose. This support allows treatment to continue safely while reducing confusion and accidental overconsumption.

36.2 Separating Cannabis From Ordinary Foods

Edibles can look similar to candy, baked goods, or common snacks. Dementia may make it harder to recognize the difference, particularly when packaging has been removed or the product is stored with ordinary food. Keep cannabis in its original labeled container and store it separately from meals and snacks. A locked cabinet or medication box may be appropriate when impulsive eating, poor judgment, or visitors create accidental exposure risk. Clear storage also protects children, pets, and other adults in the home. Products should never be placed in an unmarked bag, bowl, or food container. A reliable storage system helps you receive the intended dose while preventing another person from accidentally consuming the product.

36.3 Assigning Clear Responsibility

Medication errors are more likely when several people assume someone else has handled the cannabis. One person should have primary responsibility for obtaining, storing, measuring, administering, and documenting the product. Backup support should also be identified for times when the primary administrator is unavailable. Everyone involved should follow the same written instructions and use the same measurement device. Clear responsibility does not remove you from treatment decisions. You should still be told what you are receiving and remain involved according to your abilities. A consistent system protects your autonomy while giving your healthcare team reliable records for monitoring benefit, side effects, and future dose decisions.

37. Preventing Wandering and Unsafe Activity

37.1 Understanding Wandering Triggers

Wandering is often a purposeful response to an unmet need, even when the destination or reason is unclear. You may be looking for a familiar person, trying to reach a place from your past, searching for a bathroom, or responding to pain, boredom, noise, or a disrupted routine. Restlessness may also increase when you have too little physical activity during the day. Your care team should record when wandering begins, what happened beforehand, and whether the pattern occurs at a consistent time. Hunger, thirst, constipation, medication effects, fear, and evening confusion can all contribute. Understanding the trigger often leads to a more helpful response than simply trying to stop the movement. Medical cannabis may be considered when pain, anxiety, or severe distress appears to drive repeated unsafe walking. Treatment should focus on relieving the underlying discomfort rather than using sedation to prevent movement.

37.2 Monitoring Whether Cannabis Changes Wandering

A reduction in wandering does not always mean the treatment has solved the problem. You may walk less because pain or anxiety has improved, which can represent a meaningful benefit. You may also walk less because the dose caused sleepiness, weakness, dizziness, or reduced initiative. Your care team should compare several observations before and after each dose. Record how often you attempt to leave, how long you walk, whether you appear distressed, and how steadily you move. Also note your communication, appetite, alertness, and interest in familiar activities. A helpful response means you appear calmer, more comfortable, and easier to redirect without losing important function. If wandering decreases but you become withdrawn or unable to walk safely, your clinician should review the dose. Careful monitoring allows treatment to support comfort without unnecessarily restricting movement.

37.3 Creating a Safety Plan

A written wandering plan prepares everyone to respond consistently. It should support safe movement whenever possible while reducing the risk of becoming lost or injured. The plan may include:

• Door alerts or secured exits that follow local safety rules
• Identification jewelry or clothing
• Current photographs and emergency contact information
• Supervised walks and meaningful daily activity
• A secure garden or enclosed outdoor space
• Neighbors who know how to contact your household
• A clear search process for family and staff
• Immediate contact with emergency services when you cannot be located

Medical cannabis should fit into this plan rather than replace it. If treatment reduces pain or fear, you may wander less while remaining active. Ongoing review helps your team preserve freedom of movement while responding quickly when safety becomes a concern.

38. Driving and Transportation Safety

38.1 Dementia Related Driving Changes

Dementia can affect the thinking skills needed for safe driving. You may have difficulty following directions, judging distance, noticing traffic signs, responding to unexpected events, or finding your way through familiar areas. Delayed reactions and poor decision-making may develop gradually, which can make the changes difficult to recognize. Warning signs may include getting lost, missing turns, confusing the pedals, receiving traffic citations, or having repeated near misses. Family members may also notice new dents, slower responses, or anxiety behind the wheel. A formal driving assessment can help determine whether you can continue safely, need restrictions, or should stop driving. This decision should focus on your current abilities rather than age alone. Planning transportation early can protect your independence by giving you reliable alternatives before driving becomes unsafe.

38.2 Cannabis Related Driving Impairment

THC may affect attention, reaction time, coordination, perception, and judgment. These effects can occur even when you do not feel strongly intoxicated. Dementia may make it harder to recognize impairment or remember when a dose was taken. You should not drive after using a THC-containing product. Waiting a fixed number of hours may not guarantee safety because effects vary by route, dose, metabolism, and other medicines. Oral products can remain active much longer than expected. CBD-dominant products may produce less intoxication, but they can still cause fatigue, dizziness, or medication interactions. Your clinician should discuss driving directly before treatment begins. Clear written instructions reduce uncertainty and help you follow the same rule every time.

38.3 Planning Transportation Before Treatment

Transportation should be arranged before you begin a THC-containing treatment. This prevents a situation in which you feel obligated to drive to an appointment, a pharmacy, a store, or a family event after taking a dose. Possible options include rides from trusted relatives, community transportation, delivery services, taxis, public transit with assistance, or transportation provided by a care facility. Regular appointments can be scheduled at times when dependable help is available. Moving away from driving may feel like a significant loss, so the plan should protect your access to meaningful activities. Reliable transportation can help you continue attending medical appointments, visiting family, shopping, and attending community events. Preparing these options in advance allows you to consider medical cannabis without sacrificing connection, routine, or necessary care.

39. Eating, Swallowing, and Aspiration Safety

39.1 Recognizing Swallowing Difficulty

Dementia can gradually affect the muscles and coordination needed for safe swallowing. You may cough during meals, hold food in your mouth, chew for a long time, or develop a wet-sounding voice after drinking. Repeated chest infections, unexplained weight loss, and fear during meals may also suggest that food or liquid is entering the airway. Swallowing problems can change from day to day. Fatigue, illness, dry mouth, poor positioning, and unfamiliar foods may make eating more difficult. Your care team should observe whether certain textures, temperatures, or meal times are easier for you. Medical cannabis may support appetite, nausea relief, or meal comfort, but the chosen product must match your swallowing ability. Oils, capsules, gummies, and drinks may not be appropriate when you cannot manage them safely. Early recognition allows your healthcare team to select another formulation and preserve the benefits of treatment without increasing aspiration risk.

39.2 Avoiding Administration During Excessive Drowsiness

You need sufficient alertness to safely control food, liquids, saliva, and oral medications. When a cannabis dose causes excessive drowsiness, your swallowing reflexes and coordination may become less reliable. This can increase the chance of coughing, choking, or inhaling material into your lungs. Avoid giving food, drinks, oils, capsules, or edibles when you are difficult to wake or unable to sit upright. The person assisting you should wait until you return to your usual level of alertness and can respond normally. A dose that repeatedly interferes with meals may need to be reduced or scheduled at a different time. This adjustment does not mean the treatment has failed. Your clinician may lower the amount, select a product with less THC, or move the dose away from meal times. The goal is to support comfort while protecting your ability to eat, drink, and take medicine safely.

39.3 Coordinating With Speech and Nutrition Professionals

A speech-language pathologist can assess how safely you swallow and recommend strategies that fit your needs. A dietitian can help you maintain adequate nutrition and hydration while adapting meals to your abilities and preferences. Recommendations may include:

• Softer or modified food textures
• Thicker or thinner liquids based on testing
• Upright positioning during and after meals
• Smaller bites and slower pacing
• Direct meal supervision
• Adaptive cups, plates, or utensils
• Foods that provide more nutrition in smaller portions

Share your cannabis product, dose, timing, and observed effects with these professionals. They can help determine whether the route remains appropriate and whether treatment affects alertness during meals. Coordinated care allows appetite support and symptom relief to continue while reducing the risk of swallowing complications.

40. Supporting Communication During Treatment

40.1 Asking Simple, Concrete Questions

Dementia may make long explanations and broad questions difficult to process. Your care team can support communication by asking one clear question at a time and using familiar words. Instead of asking how the cannabis affected your overall day, they may ask whether your knee hurts, whether you feel dizzy, or whether you want to eat. Questions should allow enough time for you to understand and respond. Repeating the question quickly may increase confusion or pressure you into agreeing. Visual choices, gestures, or showing two options can help when finding the right words becomes difficult. Clear communication also supports consent. Before each dose, you should be told what you are receiving and why, using language that matches your understanding. This respectful approach keeps you involved and gives your treatment team more reliable information about your comfort and preferences.

40.2 Observing Nonverbal Responses

Your body may communicate treatment effects even when words become limited. Facial expression, posture, movement, eye contact, vocal sounds, and resistance can reveal pain, fear, nausea, relaxation, or excessive sedation. Your care team should compare these responses with your usual behavior. Relaxed muscles, easier movement, improved appetite, or greater interest in conversation may suggest benefit. Grimacing, withdrawal, poor balance, staring, or reduced engagement may signal discomfort or an unsuitable dose. Observations should be recorded in specific terms. Writing that you smiled during lunch, walked with less guarding, or remained awake through an activity provides more useful information than saying you seemed better. These details help your clinician decide whether the cannabis plan is improving comfort while preserving meaningful interaction.

40.3 Avoiding Leading Questions

Leading questions can produce unreliable answers, especially when you want to please the person asking or have difficulty remembering how you felt earlier. Repeatedly asking whether cannabis helped may encourage agreement even when the effect is unclear. Your care team should use neutral questions and objective observations. They might ask where you feel discomfort, whether you want to rest, or whether you feel different, without suggesting the expected answer. They should also compare your behavior with the written baseline. Treatment decisions should not depend on a single yes-or-no response. Sleep, appetite, pain behaviors, movement, communication, and participation provide a fuller picture. Neutral communication protects your voice and helps your clinician judge whether the product, dose, and timing are genuinely supporting your quality of life.

41. Creating a Patient-Specific Cannabis Journal

41.1 Recording Every Dose

A cannabis journal gives your healthcare team a reliable record of what you receive and how you respond. Memory changes can make it difficult to recall the exact product, dose, or timing later, so each entry should be completed when the cannabis is administered rather than at the end of the day. Record the product name, THC and CBD content, amount, route, time, and reason for use. Include whether you had recently eaten and who gave the dose. Food can affect how some oral products are absorbed, while the administrator’s name helps clarify responsibility when several people provide care. Consistency makes the journal more useful. Use the same terms and measurement units each time. A complete dosing record helps prevent repeated doses and allows your clinician to link benefits or side effects to a specific product and dose.

41.2 Recording Benefits

Benefits should be recorded as observable changes rather than broad impressions. Instead of writing that cannabis worked well, describe what you could do more comfortably after the dose. Useful changes may include:

• Fewer grimaces or pain sounds during movement
• Longer periods of uninterrupted sleep
• Greater meal or fluid intake
• Less pacing, shouting, or resistance to care
• More interest in conversation or familiar activities
• Improved tolerance of bathing, dressing, or transfers
• Reduced nausea or distress

Record when the benefit began, how long it lasted, and whether it improved the primary symptom selected for treatment. Your care team should also note whether you remained alert and able to participate in daily activities. These details help your clinician decide whether the dose is producing meaningful relief. They also show whether the effect is consistent across several days rather than based on one unusually good period.

41.3 Recording Adverse Effects

The journal should include any unwanted changes after cannabis use. Common observations may involve dizziness, unusual sleepiness, confusion, anxiety, reduced appetite, hallucinations, vomiting, poor coordination, or changes in walking. Describe exactly what happened and when it began. For example, record that you needed more help standing two hours after an edible or became unusually withdrawn after an evening oil dose. Specific details make it easier to distinguish cannabis effects from dementia symptoms or another medical condition. Also record falls, near falls, reduced drinking, changes in incontinence, or loss of usual function. One mild effect may lead to a small dose adjustment, while repeated or severe changes may require the treatment to be paused. Accurate reporting helps your clinician protect your safety while continuing to explore medical cannabis options that may better fit your needs.

42. Measuring Behavioral Symptoms Objectively

42.1 Defining the Behavior Clearly

Behavioral symptoms should be described in terms of actions that another person could observe. Words such as difficult, aggressive, or uncooperative can mean different things to different people and may not explain what you were experiencing. A clearer description might state that you paced continuously for thirty minutes, shouted during bathing, pushed a caregiver’s hand away, or attempted to leave the building twice. These details show exactly what happened and create a useful baseline before cannabis begins. Objective descriptions also protect your dignity. They help your healthcare team view behavior as communication rather than a personality problem. Once the action is defined, your clinician can identify possible triggers and decide whether medical cannabis is helping reduce distress without suppressing your ability to express your needs.

42.2 Recording Triggers and Responses

Behavior rarely appears without context. Your care team should record what happened before the behavior, how long it lasted, and what occurred afterward. Noise, pain, hunger, unfamiliar people, personal care, fatigue, or a change in routine may all contribute. The record should also include what was tried. Reassurance, food, toileting, movement, pain treatment, music, or a quiet room may reduce distress without medication. If cannabis was given, note the dose, timing, and how your behavior changed afterward. This information helps reveal patterns. You may become distressed mainly during evening care or when several people speak at once. Recognizing these patterns allows environmental changes and medical cannabis to work together rather than relying on dose increases alone.

42.3 Distinguishing Improvement From Suppression

A quieter patient is not always a more comfortable patient. Cannabis may reduce distress, but an excessive dose can also make you too sleepy, weak, or disconnected to express discomfort. Your care team should look beyond the absence of visible behavior. True improvement may include a more relaxed expression, easier redirection, comfortable movement, better communication, or renewed interest in meals and activities. Suppression may involve staring, reduced speech, inability to stand, poor eating, or sleeping through most of the day. Compare behavior with your cognitive and functional baseline. The best response supports comfort while preserving meaningful engagement. When agitation decreases without loss of alertness or function, the treatment may be meeting its goal. If you appear less active solely due to sedation, your clinician should review the dose or formulation.

43. Working With the Healthcare Team

43.1 Identifying the Coordinating Clinician

A successful medical cannabis plan needs one clinician who understands the overall treatment picture. This may be your primary care clinician, neurologist, geriatrician, psychiatrist, palliative care clinician, or medical cannabis clinician. The best choice is usually the professional who can review your dementia symptoms, other health conditions, medications, and treatment goals together. The coordinating clinician should know why cannabis is being considered and what outcome you want to measure. They should also receive updates about dose changes, side effects, falls, new hallucinations, appetite changes, or changes in alertness. Clear leadership helps prevent several clinicians from making separate recommendations that conflict with one another. Other specialists may still contribute important guidance. However, one clinician should help bring the recommendations together, confirm who manages each part of the plan, and decide when follow-up is needed. This structure allows medical cannabis to remain integrated with your broader dementia care.

43.2 Involving the Pharmacist

A pharmacist can identify medication combinations that may increase the risk of dizziness, sleepiness, bleeding, blood pressure changes, or confusion. This review is especially useful when you take several prescriptions from different clinicians. Bring a complete list that includes:

• Prescription medicines
• Nonprescription pain or sleep products
• Vitamins and supplements
• The exact cannabis product
• THC and CBD content
• Dose, route, and timing
• Recent medication changes
• Any new side effects

The pharmacist can also check whether a liquid measurement is accurate, whether a capsule can be swallowed safely, and whether two products contain overlapping ingredients. They may suggest simpler timing or help your clinician identify medicines that require closer monitoring. Pharmacist involvement does not prevent cannabis use. It gives your healthcare team more information so the treatment can be selected and adjusted with greater confidence.

43.3 Sharing the Same Plan Across Care Settings

Your cannabis plan should remain consistent when you move between home, a hospital, rehabilitation, respite care, assisted living, or memory care. Changes in staff or location can lead to missed doses, duplicate doses, or sudden treatment interruptions if the written instructions are incomplete. Keep a current document listing the product, cannabinoid content, dose, route, purpose, schedule, storage method, decision-maker, and supervising clinician. Include the symptom target, expected benefit, side effects to watch for, and conditions that require treatment to pause. Give this information to every care setting before admission whenever possible. Do not assume that staff will automatically know your state authorization or previous routine. A shared plan protects continuity, supports accurate observation, and helps your healthcare team make informed decisions when your health or care environment changes.

44. Cannabis Use in Assisted Living and Memory Care

44.1 Reviewing Facility Policies

Assisted living and memory care facilities may have their own rules for medical cannabis. State authorization does not always require a facility to store, administer, or permit every cannabis product. Policies may differ based on staffing, licensing, fire safety, smoking restrictions, or federal requirements. Before moving in or starting treatment, ask how the facility handles storage, administration, documentation, and disposal. Confirm whether staff can measure oils, divide edibles, assist with inhaled products, or record doses as needed. You should also ask who communicates with the prescribing clinician and what paperwork is required. Reviewing these details early helps avoid confusion. A facility may permit certain measurable products even when smoking is prohibited. Your clinician can then select a route and formulation that fit both your medical needs and the facility’s procedures.

44.2 Preventing Unplanned Treatment Interruptions

Medical cannabis access can be interrupted by hospitalization, rehabilitation, respite care, product shortages, renewal deadlines, or changes in facility policy. A sudden pause may make pain, nausea, poor appetite, sleep problems, or distress return. Your care team should plan ahead by tracking authorization dates, product supply, follow-up appointments, and facility requirements. Keep the product information and administration plan available for transfers. Ask what will happen if the usual product is unavailable and who must approve a substitute. Do not replace the product independently with a stronger formulation or a different route. A new product may contain a different THC concentration even when the packaging looks similar. Planning for interruptions helps preserve symptom control while reducing rushed decisions and dosing errors.

44.3 Protecting Privacy and Dignity

Medical cannabis should be discussed as a healthcare treatment, not as a reason to judge or exclude you. Staff should discuss it privately, use respectful language, and involve you in decisions to the extent of your abilities. A dementia diagnosis should not lead others to dismiss your preferences or assume you cannot understand any part of the plan. You may still be able to express whether you want treatment, how a product makes you feel, or whether alertness matters more than stronger symptom relief. Information should be shared only with people who need it for your care. Staff should also avoid discussing a patient’s treatment casually in common areas. Respectful communication protects your dignity and helps medical cannabis remain a normal, carefully managed part of your symptom care.

45. Cannabis in Palliative and Comfort-Focused Dementia Care

45.1 Clarifying the Goals of Care

Palliative dementia care focuses on comfort, dignity, and the experiences that matter most to you. Your priorities may include staying at home, reducing pain, eating with greater enjoyment, sleeping more peacefully, or avoiding burdensome medical procedures. These goals can guide whether medical cannabis fits your care plan. Your healthcare team should discuss what matters most before treatment begins. Some patients want to remain as alert and active as possible, while others place greater importance on relief from severe pain, nausea, anxiety, or nighttime distress. There is no single correct goal because treatment should reflect your values and stage of illness. Medical cannabis may support comfort when a specific symptom continues despite other appropriate care. A written goal helps your team assess whether the treatment is effective and prevents decisions based solely on sedation or reduced activity.

45.2 Balancing Alertness and Comfort

Comfort and alertness sometimes require careful balance. A small amount of sleepiness may be acceptable when severe pain, agitation, or nausea has caused prolonged distress. However, a dose that prevents you from eating, communicating, recognizing familiar people, or enjoying meaningful activities may be stronger than necessary. Your previously expressed preferences should guide this balance. You may have told family or clinicians that clear conversation matters greatly to you, or that relief from intense discomfort should take priority even if you become somewhat drowsy. Your clinician can adjust the dose, timing, and cannabinoid content to match these priorities. The aim is to reduce suffering while preserving as much engagement as you value. Regular observation helps your team determine whether the treatment continues to reflect your wishes.

45.3 Reassessing Cannabis Near the End of Life

Your body may process medicines differently near the end of life. Reduced food intake, lower body weight, changes in liver or kidney function, and increasing weakness can make a previous cannabis dose feel stronger. Swallowing may also become difficult, making oils, capsules, or edibles less practical. Your care team should reassess the product, route, and dose as your condition changes. Important considerations include:

• Whether you can swallow safely
• Whether the current route still provides timely relief
• Whether the dose causes excessive sleepiness
• Whether pain, nausea, or distress has changed
• Whether other medicines now provide overlapping effects
• Whether the treatment remains consistent with your goals

These reviews allow cannabis to continue when it provides meaningful comfort. They also help your clinician simplify or adjust treatment when another approach becomes more suitable.

46. Responding to Side Effects and Emergencies

46.1 Mild Effects That May Require Dose Adjustment

Some cannabis effects are mild and can often be managed by changing the dose, timing, or product. You may experience dry mouth, temporary dizziness, mild sleepiness, slower responses, digestive discomfort, changes in appetite, or brief anxiety. Record when the effect begins, how long it lasts, and whether it interferes with eating, walking, conversation, or personal care. A mild effect that resolves quickly may simply require closer observation, whereas a recurring pattern may suggest the dose is slightly too high. Contact your supervising clinician before making major changes. A smaller amount, lower THC content, or different dosing time may preserve the benefit while reducing discomfort. Mild side effects do not automatically mean you must stop medical cannabis.

46.2 Symptoms Requiring Prompt Medical Review

Some changes require prompt clinical guidance because they may reflect an excessive dose, medication interaction, illness, or progression of another condition. These include repeated falls, marked decline in walking, persistent vomiting, new hallucinations, prolonged confusion, unusual daytime sleepiness, or inability to eat and drink normally. Tell your clinician the exact product, THC and CBD content, dose, route, and time of administration. Also report recent medication changes, illness, poor fluid intake, or accidental additional doses. These details help determine whether cannabis caused the problem or whether another medical issue needs treatment. Do not continue increasing the dose while waiting for advice. Pause additional cannabis when instructed and provide close supervision until your usual alertness and mobility return.

46.3 Symptoms Requiring Emergency Help

Emergency symptoms require immediate medical attention rather than observation at home. Call emergency services if you become unresponsive, have chest pain, experience severe breathing difficulty, develop a seizure, or suffer a serious fall or injury. Sudden facial drooping, weakness on one side, speech difficulty, severe imbalance, or abrupt neurological change may indicate a stroke. Cannabis should never be used to manage or explain these symptoms. Keep the product container and administration record available for emergency clinicians. Tell them what was taken, how much, and when. This information supports accurate treatment and helps distinguish cannabis effects from other urgent conditions. Once the emergency has been addressed, your regular clinician can review whether the cannabis plan should resume, change, or pause.

47. Reassessing Cannabis as Dementia Progresses

47.1 Changes in Capacity and Self-Administration

Your ability to manage medical cannabis may change as dementia progresses. You may still understand why you take the product but begin forgetting whether a dose was already taken, measuring the wrong amount, or confusing cannabis with another medicine. These changes should lead to more support, not an automatic end to treatment. Your healthcare team should review whether you can recognize the product, explain its purpose, follow the dosing instructions, and report unwanted effects. Capacity may vary by time of day, so decisions should be discussed when you are most alert and comfortable. As self-administration becomes less reliable, a trusted person may need to measure, give, and document every dose. You should still be told what you are receiving and remain involved as much as possible. A structured system allows you to continue to receive potential symptom relief while reducing repeated and missed doses and preventable confusion.

47.2 Changes in Mobility, Swallowing, and Metabolism

Dementia progression may affect walking, balance, swallowing, body weight, food intake, and the way your body processes medicines. A dose that once felt appropriate may later produce stronger or longer effects because your metabolism, liver function, kidney function, or general health has changed. Your clinician should review:

• New falls, weakness, or increased need for walking assistance
• Coughing, choking, or difficulty swallowing
• Weight loss or reduced food intake
• Greater daytime sleepiness
• Changes in liver or kidney function
• New medicines or dose adjustments
• Longer-lasting effects after cannabis use

These changes may require a smaller dose, a different route, or a product with less THC. Regular reassessment helps preserve benefit while keeping the treatment matched to your current abilities.

47.3 Changes in Treatment Priorities

Your main treatment goal may change over time. Early in dementia, you may value alertness, mobility, conversation, and participation in familiar activities. Later, pain relief, appetite, sleep, emotional comfort, or easier personal care may become more important. Your cannabis plan should reflect these changing priorities. A daytime dose that once supported activity may no longer fit if balance declines. A nighttime product may become more useful if pain or distress begins interfering with rest. Your healthcare team should discuss what matters most now, not only what mattered when treatment began. Reassessing goals allows medical cannabis to remain purposeful and patient-centered. The plan can change as your needs change without assuming that progression alone means treatment should stop.

48. Knowing When to Reduce, Pause, or Stop Cannabis

48.1 No Meaningful Improvement

Medical cannabis should produce a clear and useful benefit for the symptom it was chosen to treat. If pain, sleep, appetite, nausea, or distress does not improve after an adequate and carefully monitored trial, continuing the same plan may not be worthwhile. Your clinician should review whether the dose was appropriate, whether enough time was allowed, and whether the product was used consistently. A different route, cannabinoid ratio, or timing may still be reasonable before ending treatment completely. The decision should rely on written observations rather than on a single difficult day. If repeated records show no meaningful change in the target symptom, reducing or pausing cannabis can help clarify whether the treatment is contributing anything. This approach protects you from unnecessary medication while leaving room to consider another carefully selected option.

48.2 Harm That Outweighs Benefit

Treatment should be reconsidered when side effects interfere more with daily life than the original symptom. Warning signs may include worsened confusion, hallucinations, falls, anxiety, excessive sleepiness, reduced eating, withdrawal from activities, or loss of important physical function. A mild effect may improve with a lower dose or a product containing less THC. More serious or recurrent problems may require a temporary pause while your clinician reviews the product, other medications, and potential medical causes. Stopping or reducing cannabis is not a failure. It is part of responsible treatment. Your healthcare team can use what was learned from the trial to select a safer dose, a different formulation, or another therapy that better supports your comfort and quality of life.

48.3 Conducting a Supervised Discontinuation Trial

A supervised discontinuation trial is a planned reduction or pause used to determine whether cannabis is still helping. This may be useful when the original symptom has changed, dementia has progressed, or the benefit has become difficult to identify. Your clinician should decide how quickly the dose will be reduced and what symptoms should be monitored. The care team should continue to record pain behaviors, sleep, appetite, agitation, nausea, alertness, and daily functioning during the pause. If the target symptom clearly returns and improves again after treatment restarts, cannabis may still be providing meaningful benefit. If nothing changes, the product may no longer be necessary. A structured trial gives your healthcare team stronger evidence than stopping suddenly without observation and supports treatment decisions based on your current needs.

49. Frequently Asked Questions

Choosing medical cannabis for dementia often raises practical questions beyond symptom management. These answers address common concerns that patients and families frequently have but may not encounter during routine medical visits.

49.1 Can I Travel With My Medical Cannabis?

Travel rules vary between states, healthcare facilities, and transportation providers. Before traveling, confirm that medical cannabis is permitted where you are going, keep products in their original labeled packaging, and carry only the amount you reasonably need.

49.2 How Often Should My Cannabis Treatment Be Reviewed?

Review your cannabis treatment whenever your symptoms, medications, mobility, swallowing, or overall health change. Even if everything remains stable, schedule regular follow-ups so your clinician can confirm the treatment still matches your current needs.

49.3 What Should I Do If My Regular Cannabis Product Is Unavailable?

Do not replace your usual product with another one without checking the THC and CBD content. Ask your clinician or pharmacist to recommend an equivalent option because different formulations may produce very different effects.

50. Creating the Final Written Treatment Plan

50.1 Patient Information and Treatment Authority

Your final treatment plan should begin with information that explains who you are, what type and stage of dementia you have, and how you participate in medical decisions. It should describe your usual communication abilities, level of decision-making capacity, and the support you need with treatment. The plan should identify your supervising clinician and any healthcare proxy, power of attorney, or legal representative involved. It should also record your preferences concerning alertness, comfort, symptom relief, and acceptable side effects. Include:

• Your dementia diagnosis and current stage
• Your usual cognitive and functional baseline
• Your preferred communication approach
• Your ability to consent and self-administer
• The person authorized to assist with decisions
• The clinician coordinating the cannabis plan
• Your stated treatment priorities

This information helps everyone involved follow the same patient-centered approach. It also protects your voice as care needs change.

50.2 Product and Administration Instructions

The written plan should name the exact cannabis product rather than using a general term such as oil or gummy. Record the THC and CBD content, dose, route, timing, and reason for use. Include the measuring device or portion size so each administrator gives the same amount. The instructions should state how long to wait before another dose and whether the product must be taken with food. They should also identify who obtains, stores, administers, and records it. Secure storage is essential, especially when memory changes increase the risk of repeated dosing. Keep the product in its original labeled packaging and separate it from ordinary food and other medicines. Clear instructions reduce errors and make your response easier to evaluate.

50.3 Monitoring and Stopping Instructions

The treatment plan should define one primary symptom and explain what meaningful improvement would look like. It should also list the observations to be recorded after each dose, including benefits, alertness, movement, appetite, sleep, behavior, and adverse effects. Stopping instructions should be clear before treatment begins. The plan should identify symptoms that require dose reduction, a temporary pause, prompt clinical review, or emergency help. These may include repeated falls, severe confusion, hallucinations, persistent vomiting, inability to eat or drink, unresponsiveness, stroke signs, or breathing difficulty. Include the follow-up date and the person responsible for contacting the clinician. A complete written plan allows medical cannabis to remain consistent, measurable, and responsive to your changing needs while keeping comfort, dignity, and safety at the center of care.

States Where This Condition is Approved for Medical Cannabis

Texas

Find Compassionate Dementia Support With DocMJ

At DocMJ, we provide medical marijuana evaluations, education, and personalized treatment recommendations for qualifying patients seeking symptom relief. We work with you to build a careful, clinician-supervised plan that focuses on comfort, safety, and quality of life. Take the next step to support your journey with dementia and its related symptoms.

Citations

1. Bhaskar, A., Bell, A., Boivin, M., Briques, W., Brown, M., Clarke, H., Cyr, C., Eisenberg, E., de Oliveira Silva, R. F., Frohlich, E., Georgius, P., Hogg, M., Horsted, T. I., MacCallum, C. A., Müller-Vahl, K. R., O’Connell, C., Sealey, R., Seibolt, M., Sihota, A., Smith, B. K., Sulak, D., Vigano, A., Moulin, D. E., & Ware, M. A. (2021). Consensus recommendations on dosing and administration of medical cannabis to treat chronic pain: Results of a modified Delphi process. Journal of Cannabis Research, 3, 22. https://doi.org/10.1186/s42238-021-00073-1
2. Felton, N., Lewis, J. S., Cockburn, S. J., Hodgson, M., & Dawson, S. (2021). Pain assessment for individuals with advanced dementia in care homes: A systematic review. Geriatrics, 6(4), 101. https://doi.org/10.3390/geriatrics6040101
3. Lichenstein, S. D., Scheinost, D., Potenza, M. N., Carroll, K. M., & Yip, S. W. (2022). THC, CBD, and anxiety: A review of recent findings on the anxiolytic and anxiogenic effects of cannabis constituents. Current Addiction Reports, 9, 473–485. https://doi.org/10.1007/s40429-022-00450-7
4. Lu, H. C., & Mackie, K. (2021). Review of the endocannabinoid system. Biological Psychiatry: Cognitive Neuroscience and Neuroimaging, 6(6), 607–615. https://doi.org/10.1016/j.bpsc.2020.07.016
5. Outen, J. D., Burhanullah, M. H., Vandrey, R., Amjad, H., Harper, D. G., Patrick, R. E., May, R. L., Agronin, M. E., Forester, B. P., & Rosenberg, P. B. (2021). Cannabinoids for agitation in Alzheimer’s disease. The American Journal of Geriatric Psychiatry, 29(12), 1253–1263. https://doi.org/10.1016/j.jagp.2021.01.015
6. Pautex, S., Bianchi, F., Daali, Y., Augsburger, M., de Saussure, C., Wampfler, J., Curtin, F., Desmeules, J., & Broers, B. (2022). Cannabinoids for behavioral symptoms in severe dementia: Safety and feasibility in a long-term pilot observational study in nineteen patients. Frontiers in Aging Neuroscience, 14, 957665. https://doi.org/10.3389/fnagi.2022.957665
7. Workman, C. D., Fietsam, A. C., Sosnoff, J., & Rudroff, T. (2021). Increased likelihood of falling in older cannabis users versus nonusers. Brain Sciences, 11(2), 134. https://doi.org/10.3390/brainsci11020134